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Abstract
Chapter 1 gives an introduction on the physical and electronic properties of fluorine
and the C-F bond. The application of fluorine in organic chemistry, which is mainly
attributed to the electronic properties of fluorine is described. The role of fluorine in
neuropsychiatric drug development and for influencing the conformational study of
bioactive amines is also illustrated.
Chapter 2 of the thesis describes the synthesis of the two fluorinated stereoisomers
(2R, 3S) and (2S, 3S) 3-fluoro N-methyl–D-aspartate (NMDA). These were prepared
as analogues to study the binding conformation of NMDA on the glutameric NMDA
receptor. The (2S, 3S)-3-fluoro NMDA D-72 was successfully prepared from diethyl
D-tartrate. The (2S,3R)- stereoisomer was prepared by separation of diastereoisomers
generated by reaction of a meso- epoxide with an enantiomerically pure amine,
followed by fluorination. Both the (2S,3R)- and (2R,3S)- enantiomers were prepared
separately, however assignment of the absolute configuration to each enantiomer
could not be unambiguously proven. The fluorinated 3F-NMDA stereoisomers were
assessed by dose response analysis and TEVC analysis in the rat glutamate receptor.
The biological results show that the (2S, 3S)-3F NMDA D-72 is a good agonist,
whereas (2R, 3S)- and (2S, 3R)-3-fluoro NMDA are inactive stereoisomers. The result
of this study indicates that (2S, 3S)-3F NMDA D-72 is the only relevant agonist that
can access a conformation for binding to NMDA receptor.
Chapter 3 describes the preparation of fluorinated analogues of the calcium receptor
agonist Cinacalcet. The (2R,1’R)-123 and (2S,1’R)-124 fluoro Cinacalcet
diastereoisomers were prepared from 3’-(trifluoromethyl)cinnamic acid and 3’’-SF5-
137 Cinacalcet was synthesized from pentafluorosulfanyl benzyl alcohol. The
biological assessment in the calcium receptor (CaR) revealed that both (2R,1’R)-123
and (2S,1’R)-124 fluoro Cinacalcet is slightly lower in potency compared to the non-
fluorinated Cinacalcet 117. This suggests that the Cinacalcet 117 adopts an extended
conformation when bound to the receptor. The 3’’-SF5-137 Cinacalcet possesses
equipotent activity with Cinacalcet 117.
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Chapter 1: Fluorine in organic chemistry.
1.1 Introduction
The introduction of one or more fluorine atoms in an organic molecule can significantly
alter its chemical and biological nature, including its stability, lipophilicity and
bioavailability.1 To date, around 30-40% of agrochemicals and 20% of pharmaceuticals
contain a fluorine atom.1 The exploration of introducing fluorine into a lead structure
can enhance pharmacokinetics and affinity and is a general strategy of product
development in medicinal chemistry.2 In a recent survey, it is estimated that three out of
10 drugs of the leading 100 drugs by sales, sold in 2010, contained fluorine.1
Fluorine is not only a popular tool for tweaking a drug candidate’s biological properties,
its applications have also expanded to other fields, ranging from agrochemicals to fine
chemicals. In the field of materials chemistry, flat screen technology would not be
possible without the application of fluorine in the liquid crystals.3 In the last decades,
fluoropolymers such as TeflonTM 1 and CYTOP 2 have emerged as the fluorinated
materials of choice for microchip manufacture and fiber optics.3 In just over 100 years,
the development of fluorine chemistry has been remarkable and fluorine building
blocks are becoming increasingly important in all aspect of materials science.
Figure 1.01
Structures of fluoropolymers TeflonTM 1 and CYTOP 2.
1 2
21.2 Physical properties of fluorine
1.2.1 Electronic effects
Most of the profound effects resulting from fluorine incorporation come from its
electronic properties. Fluorine is the most electronegative element in the periodic table,
consequently fluorine forms a highly polarized bond with carbon. The high
electronegativity of fluorine, introduces significant ionic character to the C-F bond.
This C-F bond presents a significant polar character, which makes it the strongest bond
between carbon and all other elements.4 The small size of fluorine means that it is a
good replacement for hydrogen without dramatically altering the molecular size.5
Table 1.0 summarizes the length and bond dissociation energy of some key bonds in
organic compounds.
Bond C-H C-C C-F C-O C-S C-Cl C-Br C-I
Length
[Å]
1.09 1.54 1.39 1.42 1.82 1.79 1.94 2.13
Energy
(KJ/mol)
416 347 485 326 259 326 64 50
Table 1.0. Bond length and bond dissociation energy for atoms bonded with carbon.4
Although fluorine is very electronegative it can also be electron donating due to the
mesomeric effect. Fluorine will stabilize carbocations and destabilize carbanions when
placed α- to the charged centre as illustrated in Figure 1.2.6 The stabilization of a
carbocation arises from the back bonding of the fluorine lone pairs into the empty
p-orbital. In the case of a carbanion, α- fluorine destabilization occurs due to lone
pair-charge repulsion.
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lone pair repulsion destabilises α-fluoro carbanions, a β-fluorine is found to
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philicity is an important parameter in the pharmacokinetics of drug design.7 In
r to tune this parameter, fluorine is considered to be a good tool for influencing the
all polarity of a molecule. This aspect has been examined systematically in several
ies.7 An early investigation by Roche was carried out on 293 pairs of molecules that
r by just one fluorine atom. The Log D is the logarithmic coefficient of the
ibution of the compound between octanol and water at a pH 7.4. A histogram of
ges in log D upon exchange of one fluorine for hydrogen was plotted (Figure 1.4).
histogram reveals that, on average the substitution of a hydrogen atom by fluorine
eases the lipophilicity by about 0.25 log units, however in some cases it reduces the
philicity as evidenced by the distribution around Log D = 0 in Figure 1.4.7
51.2.3 Fluorine as an Isostere for hydrogen and oxygen.
Fluorine has a Van der Waals radius of 1.47 Å and is a reasonable steric replacement for
hydrogen (1.20 Å) or oxygen (1.52 Å) as it causes minimal steric changes to the host
molecules. Although the size of fluorine is only slightly bigger than hydrogen, it is the
smallest atom after hydrogen to form a stable covalent bond to carbon. In terms of
bond length, the C-F bond (1.39 Å) is more similar to the C-O bond (1.42 Å) than the
C-H (1.09 Å) bond. Moreover, oxygen is the most electronegative element after
fluorine. This suggests that fluorine could be considered as a good steric and electronic
mimic of oxygen. A diversity of studies have explored fluorine in place of other
functional groups, such as the carbonyl and hydroxyl groups.8
Bond Van der Waals radius
C-F 1.47 Å
C-O 1.52 Å
C-H 1.20 Å
C-Cl 1.75 Å
C-Br 1.85 Å
C-I 1.98 Å
Table 1.1. Carbon-fluorine bond relative to other heteroatom bonds.8
Bioisosterism is a very important concept in medicinal chemistry, in which the
interchange of a functional group does not affect the potency against the biological
target of a drug candidate, but can affect the pharmacokinetics. A nice example is
demonstrated by napthyl-fused diazepines (Figure 1.5).9 Replacement of hydrogen in
an ortho position of the phenyls 3a and 4a to give 3b and 4b respectively, resulted in
enhanced affinity and efficacy. It is thought that the improvement was due to the C-F
dipole interacting with an N-H residue in the binding site.
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The metabolic stability of a drug candidate is a central concern in many drug discovery
programmes and many lipophilic compounds have a tendency to be oxidized by liver
cyctochromes P450 enzymes. One of the strategies used to overcome this is to employ
fluorine substitution to block a metabolic site. A successful example is demonstrated by
the cholesterol absorption inhibitor Ezetimibe 8.11 Drug modification was initiated
from SCH48461 7, a moderately potent compound, with two metabolically labile sites.
Introduction of fluorine atoms prevents the oxidation of the phenyl ring to phenol and
dealkylation of the methoxy group, leading to a successful drug candidate.
1.
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Figure 1.7. Development of Ezetimibe 8 from SCH48461 7.11
2.4 Acidity and Basicity
uorine substitution influences the acidity or basicity of nearby functional groups. The
a shift of several fluorinated analogues of carboxylic acids, alcohols and imides have
en evaluated. Increasing the acidity (pKa) and lowering the basicity (pKb) of organic
mpounds is a general effect of nearby fluorine due to its inductive influence. Table
2 shows the changes of pKa and pKb observed in a range of fluorinated and
n-fluorinated organic compounds.12
SCH 48461 7
ED50 (hamster )= 2.2 mg Kg-1
Ezetimibe 8
ED50 (hamster )= 0.04 mg Kg-1
8Acid pKa
C6H5COOH 4.21
C6F5COOH 1.75
CH3CH2OH 15.9
CF3CH2OH 12.4
C6H5OH 10
C6F5OH 5.5
Base pKb
CH3CH2NH2 10.7
CF3CH2NH2 5.9
Table 1.2. Acidities (pKa) of and basicity (pKb) of organic compounds in comparison
with their fluorinated analogues.12
Medicinal chemists have utilized fluorine to fine tune the pKa of amines and acids in
drug candidates. This has led to better solubility and oral absorption of drug
candidates.13 However, the effect of fluorine on the oral absorption can be
unpredictable. In medicinal chemistry, a change of pKa can have a major effect on the
pharmacokinetics of a drug. For fluorinated indole derivatives of 5HT1D ligands, the
low bioavailability due to their limited capacity to pass through membranes was
overcome by selective introduction of fluorine. As a result, the incorporation of
fluorine was found to reduce the basicity and at the same time led to improved oral
absorption. The monofluorinated analogue 10 remained a good receptor binding drug,
but with increased bioavailability. However, the difluoro compound 11 had a lower
binding affinity compared to 9 and 10, most probably due to a change of pKa making it
less basic.13
9Figure 1.8. Indole agonists to 5HT1D receptors and some pharmacokinetic data.13
1.2.5 Hydrogen bonding
In general, fluorine is a very weak hydrogen bond acceptor due to its low polarisability
and high electronegativity. The strength of hydrogen bonding for C(sp3)-F---O-H has
been estimated to be ~2.4 Kcal mol-1, less than half of the strength of C-X---O-H (5-10
Kcal mol-1), in which X is an electronegative element such as oxygen or nitrogen.14
Another important aspect which requires into consideration is hybridization. Further
evaluation on the C(sp2)-F---O-H bond strength found that it was half that of the
C(sp3)-F---O-H and was measured to be (1.48 Kcal mol-1), significantly lower than the
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IC50 = 0.3 nM
pKa = 9.7
very low bioavailability
IC50 = 0.9 nM
pKa = 8.7
medium bioavailability
IC50 = 78 nM
pKa = 6.7
9
rac-10
11
C(sp3)-F---O-H. The decreased donor ability of allylic bound fluorine as shown in
Figure 1.9 was suggested to be due to the lone pairs of fluorine which are involved in π 
conjugation with the double bond and therefore are less available to participate in
hydrogen bonding.
Figure 1.9 The F---O
bond.14
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organo-fluorine compounds form weak hydrogen bonds. This
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s demonstrated with the serine protease inhibitor factor Vlla
placement of the carbonyl group of pyrazole 13 (ki = 0.34 μm )
12 was found to have good activity (ki = 340 nm ) with (TF/Vlla).10
n was reported with a pair of serine protease inhibitors with
ty, which just differ by one fluorine atom.7 Their comparative
to the discovery of a novel serine protease inhibitor, where the
fluorinated analogue 15 (Ki = 260 nM ) is six times more potent than the
non-fluorinated inhibitor 14 (Ki = 1.6 μM).Interestingly, an X-ray co-crystal structure
study revealed that there was a conformational change when 15 is bound to human
thrombin, relative to 14 (Figure 1.10). The C-F unit of 15 favors a dipole interaction
with the N-H residue of Gly 216, which leads to a different binding mode as observed in
the co-crystal structure. This provided an insight that the C-F bond orients towards an
electrophilic centre, resulting in enhanced binding affinity.11
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1.3.2 Hyperconjugation.
Figure 1.11 Gauche effect associated with fluoroeth
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gure 1.12 Newman projection of erythro- 20 and threo-2,3-difluorobutane 21.
should be noted that the gauche effect is not limited to a hyperconjugative
planation. Wiberg has proposed a “bent-bond” analysis. By this analysis, a covalent
nd is represented by the direction of maximum electron density. In the trans-isomer
1,2-difluoroethene the electron density of the central C-C sigma bond is distorted in
posite directions resulting in a reduced overlap and weakening of the σ C-C bond.
hereas, in the case of the cis-isomer, the electron density bends towards each other
proving the overlap.24 However, recent theorectical comparisons indicate that
perconjugation is the major effect.25
15
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Figure 1.14 Dipole-dipole interactions of tricyclic thrombin inhibitor 22.26
1.3.4 Charge dipole N+….δ-F-C interactions.
The C-F bond will orient towards positive charge due to the negative dipole moment at
fluorine. Such a charge dipole interaction which is electrostatic in nature, is a much
stronger interaction compared to those interactions described so far. Synder and Lankin
first reported that 3-fluoropiperidinium 23 had a preference for the C-F bond to lie axial
23a rather than equatorial 23b. Their study has been extended to explore the structural
conformation of 3-fluorodimethylpiperidinium 24a. Despite the large steric influence
of the methyl groups, there remained a strong preference for the C-F bond to orient
axial rather than equatorial as shown in Figure 1.15.27
Figure 1.15 T
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The charge dipole interaction has subsequently been studied by different groups.
2-Fluoroethylammonium has a strong preference to align gauche 25a rather than anti
25b with respect to fluorine. DFT calculations have estimated this preference to be 5.8
kcal mol-1, favoring the gauche conformation as shown in Figure 1.16.28 The energy in
favour of the gauche preference is much larger that the stereoelectronic gauche
preference found in 1,2-difluoroethane (Figure 1.11).
Figure 1.16 The gauche conformation of 2-fluoroethylammonium 25 is stabilised by
5.8 kcal mol-1 over the anti conformation.
Other systems such as 3-fluoropyridinium salts 26 have been studied by NMR, ab initio
calculations and X-ray crystallography. Consistent with the observation above, a strong
preference for the gauche conformation is observed due to the electrostatic charge-
dipole interaction.29
Figure 1.17 The
gauche anti
25a 25b17
gauche conformation of 3-fluoropyridinium 26a stabilised by
F-C-C-N+ over the anti conformation 26b.
gauche anti
26a 26b
18
1.4 Fluorine in neurodegenerative diseases.
In the past, the positron emitting isotope F-18 has been used extensively in imaging for
the purpose of detection of brain tumors, Alzheimer’s and Parkinson’s diseases in the
CNS. More generally, introduction of fluorine improves the pharmacokinetics and
lipophilicity of drug molecules as discussed earlier, thereby allow their absorption
across the blood brain barrier. Many fluorinated drugs have been developed based on
these properties. 30
1.4.1 Drugs for depressive disorders.
Organofluorine compounds continue to make an impact in the development of
neuroleptic drugs. Lately, fluorine was incorporated into drug molecules for the
treatment of many Central Nervous System (CNS) diseases, such as depression, anxiety,
Alzhimer’s and Parkinson disease. A notable example is found in the development of
the anti-depressant drug Lexapro 28, an inhibitor for serotonin reuptake.31
Neuropsychological processes in humans such as appetite, mood, muscle contraction
and learning are modulated by serotonin 27. Serotonin is found mainly in the
enterochromaffin cells in the gut, brain and CNS.31 Over the years, serotonin receptors
have been the research target for many psychiatry and neurology disorders. LexaproTM
28 in (S)-enantiomer form is one of the large class of serotonin reuptake inhibitors
(SSRIs) that are on the market today.
27
28
1.4.2 Drugs for anxiolytics and sedatives.
Fluorobenzodiazepines 29 is another representative class of important drugs in
neurology. They work by controlling ion channel permeability to Cl- ions and as a
consequence modulate cell polarization controlled by GABAA receptors. To date, about
thirty fluorinated analogues have been developed and marketed. These include
HaloxazolamTM (rac-30), FlutazolamTM 31 and MidazolamTM (rac-32) which act in a
similar manner but are reported to be different in terms of pharmacokinetics and
pharmocodynamics.32
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E-2007TM 37 and SafinamideTM 38. E-2007TM, developed by the Eisai company is
currently being evaluated in Phase II clinical trials. It is an AMPA receptor antagonist
targeting multiple diseases such as epilepsy and sclerosis. SafinamideTM 38 developed
by the Newron company is currently in Phase III clinical trials for Parkinson’s and
Phase II for epilepsy.3221
1.5 Conformational influence of the C-F bond.
The conformational effect of fluorine substitution has not been extensively studied and
is only now emerging. The HIV protease agonist Indinavir 39 presents a good example
in this case. For Indinavir 39, the fluorinated analogue 40 is equipotent, while
compound 41 is less potent. The potency of each of the fluorinated analogues could be
attributed to the “gauche effect”, with the vicinal OH group, which either reinforces or
destabilizes a preferred binding mode for these molecules to their receptor.33
Indinavir, Ki = 1.9 nM
39Ki = 2.0 nM
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Figure 1.18 Fluorinated analogues of HIV protease inhibitors.
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GPR119 (R)-44 is an agonist of the human G-protein coupled receptor found in human
enteric L-cells and in pancreatic β-cells. It plays an important role in regulating glucose 
homeostasis and is therefore a highly desirable drug candidate for the treatment of Type
2 diabetes. A drawback of this compound was found to be its high lipophilicity (E Log
D = 4.3) which causes oxidative turnover in human liver microsomes (HLM). This led
to evaluation of the fluorinated enantiomers (S)- and (R)-45 GPR119.35 These
compounds now have a stereogenic centre containing fluorine with the fluorine β to the
nitrogen of an amide. Such amides are known to display a gauche preference found
more generally in N-β-fluoroethylamides.35 Assay results have indicated that (S)-45 has
good agonist potency, and reduced lipophilicity and oxidative metabolism in HLM. By
contrast, (R)-45 has reduced potency, most likely due to a less compatible
solution-phase conformation and unfavourable binding.35
Capsaicin 46 is an active pain stimulant that is responsible for the pungency in chili
peppers. Capsaicin is currently used as an analgesic and there is a continuous effort to
develop analogues as potent painkillers. However, the binding mode of capsaicin to its
receptor, TRPV1 remains unknown. Enantiomers of the α-fluorinated analogues of
Capsaicin have served as a tool to explore the binding conformation by comparing the
relative efficacy of the two enantiomers. It emerged that the two enantiomers (R)-47
and (S)-47 have the same efficacy as Capsaicin.36 As a result, it is suggested that the
two fluorinated analogues bind to TRPV1 in an extended conformation as shown in
Figure 1.20. This conclusion was also in agreement with a previous model study,
which concluded the extended chain of capsaicin aligned parallel to the lipid chain of
the membrane.36
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Figure 1.22. (S)- and (R)-3F-GABA 49 docked into the p1 GABAC receptor ligand
binding site.38
Figure 1.23. Comparison of the preferred binding mode of GABA to GABAA and
GABAC receptors.
On the other hand, when both enantiomers were analysed with GABA aminotransferase,
only (3R)-fluoro GABA 49 had high efficacy as a substrate for the enzyme. From this
experiment, it was deduced that the preferred binding conformation of GABA to
GABA-transaminase was conformation B (Figure 1.21).37
GABAA receptor binding mode GABAC receptor binding mode
1.6 Towards predicting the conformational activity relationship on
glutameric-NMDA receptors.
Evidence emerging from animals and receptor binding studies has shown that
overactivation of the glutamate receptor leads to numerous neurological disorders.39
N-Methyl-D-aspartate (NMDA) is an agonist of the glutamate receptor which induces
reasonable activity in electrophysiological studies and was the focus in this
conformational-activity study to gain an insight into binding at the glutamate receptors.
The current tools used to explore binding conformation include co-crystallization of the
corresponding receptors with agonist or by preparing a series of analogues to
understand key binding residues. However, some of these techniques have limitations
or drawbacks. The C-F bond as the most polar bond was envisioned as a conformational
tool to explore the binding mode of different bioactive molecules. Numerous examples
have shown that the C-F bond can influence the conformation of an organic molecule,
especially when incorporated adjacent to other functional groups. As a consequence of
this, two bioactive molecules were chosen as the targets in this study. Our first target
involves the preparation of 3F-NMDA diastereoisomers 72 and 73 to explore the
glutamateric NMDA receptors. The synthesis of 3F-NMDA 72 and 73 diastereoisomers
and their biological study on glutamate receptors are described in the chapter 2.
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important binding mode of this drug, for future drug development program. As part of
this study, the CF3-substituent of Cinacalcet HCl 117 will be swapped with the
SF5-substiuent to generate 137 to explore the relative efficacy between these two
substituents.30
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Chapter 2: Synthesis and biological studies of 3-fluoro
NMDA stereoisomers.
2.1 Introduction
Neurodegenerative disorders, such as Ischemia, Alzhimer’s, Parkinson’s and
Huntington’s are diseases associated with progressive memory impairment, paranoia,
delusion and decline in language function.1 All these physiological functions
including memory and learning, are modulated by brain regions in which glutamate is
the principal excitatory neurotransmitter. Evidence from in vivo and in vitro studies
indicated that GluR-induced toxicity is associated with Alzhimer’s disease.1
2.1.1 The glutamate receptor in the mamalian CNS.
The glutamate receptor falls into two categories, namely the metabotropic receptors
(mGluR) and the ionotropic receptors (iGluR). The iGluRs can be further divided into
three sub-classes, namely the N-methyl-D-aspartate (NMDA), kainic acid (Kainate)
and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors.2
These three sub-classes are cation permeable and are thought to be involved in key
processes, such as learning and memory.2 The mGluRs which comprise subclasses
I-III are found to conduct slow modulating responses through G-protein-coupled
receptors by depolarization of the membrane potential. It is generally agreed that
mGluRs and iGluRs are responsible for many neurodegenerative diseases in the CNS,
and all of these subunits have important potential for therapeutic interventions.2 The
structures of iGluR agonists, namely the AMPA 50, kainate 51, NMDA 52 and
glutamate 53 are shown in Figure 2.1.
Figure 2.1 Structure of iGluR agonists: AMPA 50, Kainate 51, NMDA 52 and
Glutamate 53.
Structurally, the iGluR and mGluR receptors are composed of heterogenous protein
subunits. For example, four sub-units (GluA1-4) for AMPA and five sub-units
(GluK1-5) for Kainate receptors. The NMDA receptor has up to seven sub-units,
namely the GluN1, Glu2A-D and Glu3A-B. The mGluR are similarly complex as
illustrated in Figure 2.2.2
Figure 2.2 S35
ub-units identified in NMDA, AMPA, KA receptors and mGluRs.2
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2.1.2 The binding domain of glutameric NMDA receptors.
Activation of glutamate receptors requires the binding of both glycine and glutamate
58, where GluN1 and GluN2 contain the binding sites of glycine and glutamate
respectively. The glutamate receptors are both ligand and voltage sensitive. Once
activation occurs, the ion channel allows the flow of Na+ and Ca2+ into cells while
releasing K+. The influx of Ca2+ through the receptor to postsynaptic cells, allows the
conversion of an electrical to a biochemical signal to trigger a synaptic response.3 The
depolarization of the ion-channel is subsequently carried out by the inhibition of
magnesium on glutamate receptors.
Ionotropic glutamate receptors comprise different functional domains as illustrated in
Figure 2.3, namely the amino terminal domain, the ligand binding domain, the
membrane associated region and the intracellular carboxyl domain. Armstrong et al.
reported that the ligand binding domain is formed of S1 and S2 protein regions which
are thought to form a hinged clamshell-like structure.4 Chen et al. reported that the
AMPA and kainate subunits in bacterial glutamate receptors have a very high degree
of similarity to those observed in human NR2 NMDA receptor subunits.5
Figure 2.3. Cartoon structure of an ionotropic glutamate receptor comprising ligand
binding domains S1 & S2, re-entrant loop (M2), amino terminal domain and the
carboxyl terminal domain.6
Before that, the mechanism of binding of glutamate to the NR2 subunit was not well
understood. Most of the partial and full agonism studies were conducted using site
directed mutagenesis to identify key binding residue in the binding pocket. Indeed, the
result of these studies showed that the NR2 subunits had a higher degree of homology
that the corresponding AMPA subunits. In 2005, Furukawa et al. reported the first
X-ray crystal structure of the NR2A agonist binding site co-crystallized with
glutamate as shown in Figure 2.4.7 This X-ray structure was interrogated by
molecular modelling to further explore the different residues involved in the binding
of glutamate to the NR2A subunit.
Figure 2.4 Th
The glutamate
carboxylic grou
116A, Asp21537
e X-ray derived structure of NR2 with bound glutamate viewed from
two different angles.7
is shown to bind to the receptor in an extended conformation, with the
ps forming ionic interactions with the N-H residue from Arg11A, Thr
A and Thr 174A. The protonated amine contacted two residues of the
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binding site, namely Thr 116A and Ser 114A (Figure 2.5 A). During the later stages of
this research, the structure of NMDA co-crystallized with GluN1/N2D NMDARs was
reported by Furukawa et al. in 2011.8 Interestingly, the structure with NMDA shows
that it adopts a different binding mode, with its methylamine group and one of the
carboxylates forming ionic interactions with Thr 116A. The other residues Thr 174A,
Ser 173A and Arg 121A form ionic interactions with the carboxylic groups of NMDA
(Figure 2.5 B). Overall, the receptor induces a folded binding mode for NMDA.
Figure 2.6 summarizes the binding mode of glutamate and NMDA into the
GluN1/N2D receptor.
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Figure 2.5 The extended conformation of glutamate (A) and folded conformation (B)
for NMDA when bound into the active site of the GluN1/N2D receptor.
Figure 2.6 The preferred binding mode of glutamate and NMDA when bind into the
GluN1/N2D receptor.
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2.1.3 Agonists and antagonists of glutamate receptors.
The pharmacological description of the various glutamate receptors derive from the
structure of agonists and antagonists. Such excitatory amino acids (EAA) are
important for modulating different glutamate receptors and they serve as
pharmacological tools and are useful therapeutics for the future.
Over the decades, a large number of potent agonists and antagonists have been
discovered. The glutamate structure can often be identified within these compounds.
Among these, (S)-2-amino-3-(N-oxalylamino)propionic acid (β-ODAP) 54,
rac-tricholomic acid 56, ibotenic acid 55, willardiine 57 and quisqualic acid 58 are
very potent, but unselective agonists.9 These amino acids have acted as model
structures for lead development of neuroactive drugs.
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A range of glutamate receptor antagonists have been developed and are in early
clinical trials for the treatment of stroke. Relevant antagonists are the non-competitive
channel blocker aptiganel 59, the competitive glycine site antagonist ACEA-1021 60,
the competitive glutamate antagonist Selfotel 61 and the Ifenprodil analogue Eliprodil
62. These compounds were hampered by unwanted side effects, such as respiratory
depression and cardiovascular dysregulation. Furthermore, Selfotel and Eliprodil have
shown reduced side effects but these compounds were withdrawn during the early
clinical stage due to a lack of efficacy at tolerable doses.10-11
2.1.4 The pharmacology of NMDA receptors and it subunits.
There are many well documented examples showing that NMDA or related
compounds are found to be neurotoxic to glutamate receptors. Neuronal death linked
to epilepsy appears to be highly dependant on NMDA receptor activation, while
neuronal degeneration such as ischemia is caused by both NMDA and AMPA
receptors.12 It is important to note that the NMDA receptor plays a number of roles
associated with crucial physiological and pathological brain processes. More recently,
it has been shown that different subunits correspond to different expression levels,
with NR2B restricted to the forebrain, NR2C to the cerebellum and NR2D is much
rarer than the other subtypes. This differential subunit assembly allows sub-unit
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selective compounds to be developed, for instance NR2B is selectively blocked by
Ifenprodil.13 On top of this, Zn2+ was also reported to be a natural antagonist to the
NR2A subunit.14 The sub-type selective ligands that bind to the NMDA receptors are
illustrated in Figure 2.7.
Figure 2: Model structure of glutameric NMDA receptor.5
Figure 3. Model structure of NMDA receptors.
Figure 2.7 Sub-units selective antagonists ligands of the NMDA receptors.15
Although NMDA receptors subtype have been known for 30 years, details of the exact
binding mode of glutamate and NMDA are only emerging from X-ray structural
biology (Figure 28). Early studies involved comparing the relative efficacy of ring
systems of restricted rotation. For example Erreger et al, prepared glutamate agonists
of type 63-7116. Compound 64 was as potent as glutamate on the NR2A and NR2B
subuits, but it exhibited a much higher potency in the nano-molar range with NR2C
and NR2D subtypes. However, the increase of the ring size from cyclobutyl to
cyclopentyl was found to decrease potency and efficacy, with a 10 fold decrease for
cylcobutyl and a 20 fold decrease for cyclopentyl. Similarly, compounds 69-71 were
found to be biologically inactive probably due to unfavorable binding modes. In this
experiment, it is very clear that low molecular weight molecules are ideal compounds
for glutamate receptor binding.
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2.1.5 Therapeutic prospects of NMDA analogues.
A substantial amount of research has shown that the NMDA receptor is a promising
target for preventing the progression of neurodegeneration. Diseases such as
Alzheimer’s, Parkinson’s, Huntington and Ischemia are associated with glutamate
toxicity, therefore novel NMDA antagonists are of interest. Unfortunately, most of the
current NMDA antagonists induce side effects, which also suppress learning and
memory. Therefore, there is value in studying the binding conformation of both the
NMDA agonist and antagonist to their pathologically active receptors.
44
2.2 Aim of this Project
Following the 3F-GABA research in St. Andrews,17-18 it became an objective to
explore the influence of the C-F bond on the conformation of NMDA and thus
explore the conformational requirement for NMDA binding to its receptors. Figure
2.8 shows that each 3F-NMDA stereoisomer is limited to a set of three staggered
conformations. It is anticipated that the C-F---NH3+-C interaction will bias the
conformation such that the C-F and C-N+ bonds are gauche. The Newman projections
show that the diastereoisomers 72 and 73 are likely to show different levels of activity,
as they are predicted to adopt different favoured conformers in solution.
Figure 2.8 Newman projection of D-3F-NMDA diastereoisomers.
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The aim of this project was to develop a method for the synthesis of individual
diastereoisomers of D-3F-NMDA and to assess their efficacy as glutamate receptor
agonists. There are four possible stereoisomers of 3F-NMDA which are shown in
Figure 2.9. Stereoisomers D-(2S,3S) 72 and 73 (2S,3R) were the key targets in this
research programme as they have the required D-configuration.
Figure 2.9 The four possible stereoisomers of 3F-NMDA.
2.3 Background on the synthesis of 3F-NMDA.
3-Fluoro D-aspartate is a close structural analogue of 3F-NMDA.19-20 An enantiomeric
pure synthesis of 3-fluoro D-aspartate was reported by Charvillion et al.21 In this route
(Sceheme 1), (2S,3S)-3F-D-aspartic acid 78 was prepared from (2S,3S)-epoxy
succinate 74 in three steps. The key step involved a deoxofluorination reaction of 75
to obtain 76, a reaction that proceeds by a double inversion of configuration. This was
achieved with DASTTM or DeoxofluorTM. The mechanism of formation of 76 is
thought to proceed via a three member aziridinium ring, followed by ring opening
with fluoride ion to generate 76.
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Scheme 2.1 Reagents and conditions: a) HNBn2, LiBF4, CH3CN, reflux, 72 h, 62%; b)
Et2NSF3, THF, RT, 2 h, 94 %; c) H2, (1atm) Pd/C, EtOH, 4 h, quant.; d) HCl 4N,
reflux, 48 h, 40 %.22
By contrast, the syn isomer (2S,3R)- 83 (Scheme 2) was accessed by forming cyclic
sulfate 79, which was derived from diisopropyl D-tartrate. Ring opening of the cyclic
sulfate by TBAF proceed with an inversion of configuration to generate fluorohydrin
80, which was then converted to the corresponding triflate. Displacement of the
triflate with sodium azide, followed by hydrogenation to the amine and then acid
hydrolysis gave (2S,3R)-3F 83 as a single enantiomer.
Scheme 2.2 Reagents and conditions; a) 1. Et4NF, acetone, RT, 6 h; 2. H2SO4, 20%
aqueous solution, RT, 7 h, 88%; b) 1. Tf2O, CH2Cl2, -65 °C, 5 min then 2, 6-lutidine;
2. NaN3, DMF, -5 °C, 56%; c) H2, (1 atm) Pd/C, EtOH, 4 h, quant.; d) HCl 4N, reflux,
20 h, 53 %.22
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2.4 Result and Discussion
2.4.1 Retrosynthetic analysis of 3F-NMDA.
Our retro-synthetic approach to diastereoisomer (2S,3S)-3F-NMDA D-72 is shown in
Scheme 2.3. Target D-72 is accessible by hydrolysis of diethyl ester 90. Access to 90
was envisaged by deprotection of N-benzyl or N-para-methoxy groups. The key step
in this route lies in the fluorination of alcohol 88 to give 89 and then ring opening of
epoxide 87 with an appropriate methylamine. The preparation of epoxide 87 follows
from the literature.22 The retrosynthetic analysis of (2S,3R)-3F-NMDA D-73 differ
from the above, with 96 synthesized as an intermediate to facilitate the single fluoride
inversion leading to 97. The rest of the route will be the same as that reported for D-72.
The envisaged synthetic route towards the first single diastereoisomer D-72 is outlined
in Scheme 2.4.
Scheme 2.3 Retrosynthetic analysis of 3F-NMDA diastereoisomers of D-72 and D-73.48
Scheme 2.4 Proposed strategy towards the (2S, 3S)-3F NMDA D-72.
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2.4.2 Synthesis of (2S, 3S) 3-fluoro NMDA D-72.
Epoxy succinyl dipeptides have gained considerable attention due to their novel
applications as cystein-protease inhibitors.23 Accordingly, this has further encouraged
the optimization of synthetic protocols for the synthesis of epoxy succinyl moieties.
The trans-epoxy succinic ester 87 could be accessed from diethyl (-) D-tartrate 84 in
three steps following the procedure of Korn et al.22 In this route, bromoacetoxy ester
85 was prepared by treating 84 with hydrobromic acid in acetic acid. The mechanism
for the formation of 85 is proposed by Golding et al. to proceed as illustrated in
Scheme 2.6.24 Fractional distillation afforded 85 in good yield (94%). This product
was then treated with sodium ethoxide in ethanol to give a satisfactory yield (52 %) of
epoxide 87.
Scheme 2.5. Synthesis of epoxy succinate 87 from 84. Reagent and conditions: a)
HBr/AcOH, RT, 4 h ; b) HBr/AcOH, EtOH, 85 °C, 97%; c) EtONa, EtOH, rt, 2 h, 57
%.
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Scheme 2.6. Proposed mechanism by Golding et al. for the formation of 85.24
A key step in the synthesis of (2S,3S)-3F 72 lies in the ring opening of epoxide 87
with an appropriate amine. Several attempts were explored. This included treating
epoxide 87 with methylamine in ethanol under reflux. However, this proved
unsuccessful due to methylamine attacking the ester to generate diamide 92 as
illustrated in Scheme 2.7 a. Upon repeating the same reaction, but with the diisoproyl
ester 93 to suppress amide formation, it was found that only the monoamide 94 was
generated, but no ring opening occurred as illustrated in Scheme 2.7 b. Finally,
success was achieved by reacting diethyl ester 87 with the less nucleophile amine,
benzylmethylamine (Scheme 2.7 c). This time the reaction gave 88 in 85% yield after
chromatography. This proved satisfactory and allowed preparation of an appropriate
substrate for the important fluorination reaction.
85
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Scheme 2.7 Reagent and conditions: CH3NH2, EtOH, 85 °C, a) 74%; b) 50%. c)
BnMeNH, EtOH, 85 °C, 85%.
Dehydroxyfluorination of alcohol 88 proved to be a straightforward reaction.
Treatment with DeoxofluorTM afforded the fluorinated product 89 in 93 % yield and
as a single diastereoisomer. Substitution of the hydroxyl group with fluorine is
anticipated to proceed by a double inversion process, and thereby with an overall
rentention of stereochemistry. Ring opening of the aziridinium (Scheme 2.9) by
pathway (a) and (b) give an identical product. Indeed, the 19F NMR only showed one
peak (at –195.0 ppm) consistent with a single isomer 89. A proposed mechanism for
the formation 89 is outlined in Scheme 2.9. In order to establish that the reaction did
indeed proceed with a retention of configuration, it was desirable to prove relative
stereochemistry by X-ray crystal structure analysis. However, this proved difficult, as
product 89 reacts with HCl in ether to form a rearrangement product (Figure 2.12)
and the proposed mechanism of the rearranged product is illustrated in Scheme 2.10.
Another attempt was made to make the cyclohexylamine derivative of 89.
Disappointingly, defluorination occurred again. The stereochemical proof of this
synthesis step will be discussed later.
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Scheme 2.8 Synthesis of fluoro analogue 89 from 88. Reagent and conditions: a)
Et2NSF3 (3 equiv), DCM, RT, 2 h, 93%.
Scheme 2.9 Proposed mechanism for the formation of 89 proceeding via an
aziridinium intermediate and with overall retention configuration at C-3. Ring
opening by either pathway (a) and (b) gives an identical stereoisomer.
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Figure 42. 1H NMR of fluorination product 91.
Figure 2.10 1H-NMR of fluorination product 89.
Figure 2.11 19F-NMR of fluorination product 89 indicating a single stereoisomer.
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Figure 2.12 X-ray crystal structure of 91 the product resulting from the reaction of 89
in HCl-ether.
Scheme 2.10 Proposed mechanism for the formation of triethyl oxalocitrolactone
ester 91 in HCl-ether.
With the fluorine successfully in place, deprotection of the benzyl group of 89 was
investigated by hydrogenation as shown in Scheme 2.11. The deprotection was
performed with hydrogen using palladium on activated carbon as a catalyst in ethanol.
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The reaction was followed by TLC until the starting material was consumed. Work up
afforded product diester 90 in a good yield and this product was used for subsequent
reaction without further purification.
Scheme 2.11 Deprotection of 89 by hydrogenation. Reagent and condition: a) H2,
Pd/C, EtOH, RT, 2 h, 97%.
The final step in the synthesis of (2S, 3S)-3F D-72 involved acid catalyzed hydrolysis
of diethyl ester 90. The experiment was successfully carried out by treating diester 90
with HCl (4M) at 80 C for 48 hours.
Scheme 2.12 Synthesis of (2S, 3S)- 72 from 90. Reagent and condition: a) 4 M
HCl/H2O, 85 °C, 50 %.
With the completed synthesis of erythro (2S, 3S)-3F NMDA HCl D-72, this gave the
first sample of a 3F-NMDA diastereoisomer. The optical rotation of D-72 was
measured and compared to that of erythro (2S, 3S)-3F aspartic acid 78. Interestingly
both have the same sense of rotation, with the [α]D for D-72 and 78, found to be -7.2°
and -18.0°, respectively. 19F-NMR analysis of both D-72 and 78 showed signals at
-198.5 ppm and -198.5 ppm respectively, suggesting that these are the related
stereoisomers. The 19F-NMR of threo is -196.0 ppm, which is 2 ppm difference
56
between the diastereoisomer series. With D-72 in hand, it was now important to
prepare the second diastereoisomer.
2.4.3 Synthesis of (2S, 3R) 3-fluoro NMDA D-73.
The synthetic route to (2S, 3R) 3-fluoro NMDA D-73 is outlined in Scheme 2.13. The
route is a modification of the above pathway, but designated to attempt a single
inversion of configuration during the fluorination reaction, rather than a double
inversion. To achieve this, nucleophilic ring opening of a cyclic sulfamate was
envisaged to generate (2S,3R) 3-fluoro NMDA D-73.
Scheme 2.13. Proposed route to (2S, 3R)- D-73.
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The routes to the two stereoisomers diverge at alcohol 88. Amino alcohol 95 was
readily accessed by hydrogenation of 88 as shown in Scheme 2.14. The procedure for
the hydrogenation was straightforward and the reaction was followed by TLC until
complete conversion had occurred. Simple filtration and solvent removal afforded 95
in good yield.
Scheme 2.14 Reagent and condition: a) H2, Pd/C, EtOH, RT, 2 h, 97%.
The route was progressed by subjecting amino alcohol 95 to treatment with thionyl
chloride and sodium meta periodate and cat. RuCl3.3H2O. The reaction was carried
out according to the method of Marcian et al.25 This generated the cyclic sulfamate 96
as illustrated in Scheme 2.15.
Scheme 2.15. Synthesis of 96 from 95. Reagents and conditions: a) Et3N (2 equiv),
SOCl2 (1.2 equiv), DCM, – 78 C, 2 h, RT, 16 h; b) NaIO4 (2.0 equiv), RuCl3.3H2O,
CH3CN/H2O (1:1), 0 C, 4 h, 75%.
It was envisaged that cyclic sulfamate 96 could then be treated with a fluoride ion
source to generate 97. However, this proved unsuccessful with TBAF. All of the
starting material was converted into a new product, but no fluorine was incorporated.
The actual product could not be characterized, however it presumably arose due to a
fluoride ion promoted elimination reaction. Therefore, this synthetic route was
discontinued and a new approach to this threo stereoisomer was considered.
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Scheme 2.16. Unsuccessful attempt towards the synthesis of 97.
2.4.4 Synthesis of threo (±)(2SR,3RS)-3F NMDA from diethyl maleate
98.
An alternative approach to the threo stereoisomer of 3F-NMDA was explored as
shown in Scheme 2.17 from the meso-epoxy succinate 99.26 Accordingly, diethyl
maleate 100 was treated with t-BuOOH and nBuLi and the excess of peroxide was
quenched with sodium sulfide. Work-up gave the meso-epoxide 99 after column
chromatography, in about 50 % yield.
In order to explore whether this epoxidation reaction proceeded stereospecifically to
generate only the cis-epoxide, the 1H NMR of this product was compared to that of a
reference sample of the trans-epoxide. The spectra are shown in Figure 2.13, and
they are clearly different entities. To be conclusive both cis and trans epoxides were
add- mixed as shown in the lower spectrum of Figure 2.14. The result was very clear
indicating that both 87 and 99 are different geometric isomers, and that the basic
peroxide reaction was stereospecific.
Ring opening of epoxide 99 in an ethanol with benzylmethylamine gave racemic
alcohol 100 in good yield (92%). With rac-100 in hand, a deoxofluorination reaction
was performed and as anticipated, fluorination afforded 101 also in good yield (84%).
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Subsequently, deprotection of rac-101 was performed by hydrogenation and
β-fluoroamine rac-102 was recovered in a straight forward manner in 87% yield.
Finally hydrolysis of diethyl ester rac-102 was performed in 4M HCl. Examination of
the literature21 found that acid hydrolysis under reflux gave the best yield, however,
this turned out to be a sluggish reaction and the yield is not always good (30%). The
overlay of 1H-NMR spectrum of D-72 and rac-73 were shown in Figure 2.14.
Scheme 2.17. Reagents and conditions: a) tBuOOH (2 equiv), nBuLi (1.2 equiv), THF,
– 78 C, 30 min, RT, 16 h, 50%; b) BnMeNH2, EtOH, 85 °C, 92%; c) Et2NSF3 (3
equiv), DCM, RT, 2 h, 87%; d) H2, Pd/C, EtOH, RT, 2 h, 87%; e) 4 M HCl/H2O, 85
°C, 48 h, 30%.
Figure 2.13. The 1H-NMR of (2S,3S)-87, (±)(2SR,3RS)- 99 and the mixture of both
isomers spectrum recorded in CDCl3 at 300 MHz).
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2.4.5 Improved synthesis of threo (±) 73.
A new approach to threo (±)-73 was considered. This was required as threo (±)-73
prepared from the diethyl maleate was subject to decomposition and low yields in the
last step after long reaction times in concentrated HCl. As a result, an improved route
leading to a higher yield of threo (2SR,3RS)-3F (±)-73 was developed and is outlined
in Scheme 2.18. This time threo (±)-73 was prepared from the dibenzyl ester rather
than the diethyl ester. Accordingly, diacid 103 was treated with oxalyl chloride and
triethylamine to generate the diacid chloride, which was used without purification.27 It
was then treated with 2.1 equivalents of benzyl bromide. A catalytic amount of DMF
and pyridine afforded epoxide 104 as colorless oil in 86% yield.
Ring opening of epoxide 104 with benzylmethylamine, via the now established
method gave rise to 105 in good yield (92%) and then subsequent deoxofluorination
of 105 afforded fluoroamine 106. With 106 in hand, the final hydrogenation reaction,
to remove all three benzyl groups, was explored with Pd/C and hydrogen. Celite
filtration and concentration under reduce pressure afforded (±)-73 in a high yield
(86%). Overall, this dibenzyl maleate synthetic route gave a more satisfactory yield of
(±)-73 in comparison to the diethyl ester approach.
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Scheme 2.18 Improved route to threo (±)-73 involving benzyl deprotection.
Reagents and conditions: a) (i) (COCl)2 (1.2 equiv), DMF, Et3N (2 equiv), THF, –78
C, 30 min, reflux 2 h, 86% ; (ii) BnOH (2.1 equiv), py, THF, RT, 16 h, 92%; b)
BnMeNH, EtOH, 85 °C, 84%; c) Et2NSF3 (3 equiv), DCM, RT, 2 h, 84%; d) H2, Pd/C,
EtOH, RT, 2 h, 86%.
2.4.6 Enantiomer resolution from racemic (2SR,3RS)-3F NMDA HCl
73.
Resolution of a single enantiomer of threo 73 was investigated involving
diastereoisomeric separation of a suitable intermediate. The approach taken is outlined
in Scheme 2.19 and 2.21. Diastereosiomers (S)-107 and (S)-108 were prepared by
treating the meso 104 with the enantiomerically pure base, (S)-(-)-N,
α-dimethylbenzylamine as shown in Scheme 2.19 to generate two diastereoisomers. 
Fluorination of this diastereoisomeric mixture was then carried out with DeoxofluorTM.
Neighbouring group participation during the deoxofluorination generates an aziridium
ring which has two electrophilic sites. Attack by fluoride ion at each of these centres
affords a different diastereoisomer in each case as shown in Scheme 2.20. Therefore,
the diastereoisomeric mixture of alcohol (S)-107 and (S)-108 was used directly in the
deoxofluorination reaction without separation as shown in Scheme 2.21. The
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chromatographic separation of the resultant fluorinated diastereoisomers (S)-109 and
(S)-110 after deoxofluorination was difficult, but a single diastereosiomer was isolable
after careful chromatography. The second diastereosiomer could not be purified as a
single compound, as the separation was always accompanied by the other
stereoisomer. Therefore, in order to obtain a pure sample of the second stereoisomer,
104 was treated with (R)-(+)-N, α-dimethylbenzylamine, the other enantiomer of the
base, and the protocol repeated.
Scheme 2.19 Reagents and conditions: a) (COCl)2 (1.2 equiv), Et3N (2 equiv), THF,
–78 C, 30 min, reflux 2 h ; b) BnOH (2.1 equiv), DMF, py, THF, RT, 16 h, 86%; c)
(S)-(-)-N,α-dimethylbenzylamine, DMF, 160 °C, 85%; d)
(R)-(+)-N,α-dimethylbenzylamine, DMF, 160 °C, 89%
64
Scheme 2.20 Deoxofluorination of single diastereoisomer (S)-107 leading to
diastereoisomers (S)-109 and (S)-111.
Scheme 2.21 Preparation of enantiomers (-)-73 and (+)-73. Reagents and conditions:
a) Et2NSF3 (3 equiv), DCM, RT, 2 h, 43%, resolution by silica column
chromatography; b) H2, Pd/C, EtOH, RT, 2 h, 85%; c) 1 M HCl.
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In this way, both stereoisomers could be obtained as pure compounds, however the
absolute configuration of each diastereoisomer 109 or 110 could not be determined.
Stereoisomers 109 and 110 were subjected to hydrogenation to furnish the
end-product (2S,3R)- and (2R,3S)-3F- NMDA HCl with the absolute stereochemistry
yet to be confirmed. The 1H- and 19F- NMR of the enantiomers were of course
identical, and identical too to racemic threo, with 3JHH and 3JHF coupling constants
found to be 27.0 Hz and 45.0 Hz, respectively. X-ray crystal analysis of a suitable
crystal of (-)-73 confirmed the relative stereochemistry and showed that 3F-NMDA
clearly adopts a gauche relationship between C-F—C-N+ with a dihedral angle of
62.7°.28 The structure had an extended conformation with the carboxylate groups
anti-periplanar to each other as illustrated in Figure 2.15.
Figure 2.15 X-ray structure of (-)-73 showing an extended conformation and a C-F to
C-N+ dihedral angle of 62.7°. The absolute stereochemistry is arbitrarily shown.
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Figure 2.16 1H NMR spectra of (-)-73 and (+)-73 recorded in D2O at 300 MHz.
Figure 2.17 19F NMR spectra of (-)-73 and (+)-73 recorded in D2O at 300 MHz
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Stereosiomers (-)-73 and (+)-73 were explored in a diastereomeric ratio study to
assess if even minor levels of the opposite diastereomers 72 could be present in the
sample. The signal at -198.6 ppm corresponds to erythro-72, while that at -196.4 ppm
corresponds to the threo-73. The chemical shift differences are consistent with two
separate diastereoisomers, and neither sample was contaminated with the other,
indicating a very high diastereomeric ratio of erythro-72 and threo-73.67
Figure 2.18. 19F NMR spectra of erythro-72 and threo-73 recorded in D2O at 300
MHz.
erythro-72
threo-73
68
2.4.7 pKa studies
The high electronegativity of fluorine will clearly affect the pKa of the adjacent
functional groups (NH2 and COOH) relative to NMDA. It is well documented that the
pKa of carboxylic acids, alcohols and amines are reduced by fluorine substitution α or 
β to the functional groups.29 This is illustrated in Table 2.0 for fluoroalanines. The
successive introduction of fluorine increases the acidity of the carboxylic groups by
upto 0.9 of a pKa unit, while it causes the amine to become less basic by upto 4.0 pKa
units as we progress along the series from –CH3 to –CF3.29
R CH3 CH2F CHF2 CF3
pKa (CO2H) 2.3 2.4 1.5 1.2
pKa (NH2) 9.9 9.8 8.4 5.3
Table 2.0. pKa of fluoroalanines.28
Similarly, it is therefore relevant to measure the pKa of 3F-NMDA HCl D-72, as the
fluorine will influence the electronics relative to NMDA. In particular lowering the
pKa of the amine could affect the protonation status in vivo. A potentiometric titration
of NMDA HCl 52 was established as a control. The measurement was carried out in
deionised water (2 ml) at 25° C, in a (2.3 mmolar) solution of 52 in a temperature
controlled water bath. A pH electrode designed for small volumes was calibrated
using standard solutions of pH 4 and pH 7. The NaOH solution (2.3×10-2 mol.L-1)
was calibrated with a known concentration of tartaric acid using phenolphthalein as an
indicator. The pKa values for NMDA HCl can be read from the curve as show in the
Figure 2.19 (i). The pKa values for NMDA HCl were found to be 2.63 (pKa1), 4.02
(pKa2) and 10.22 (pKa3). The same analysis was then carried out for (2S,3S)-3F
NMDA 72 and the resultant curve is shown in Figure 2.19 (ii).
(i) Potentiometric titration of NMDA HCl 52
pH
pKa = 2.63
pKa = 4.02
pKa = 10.22
(ii) Potentiometric titration of (2S,3S)-3F D-7269
Figure 2.19 pKa titration curve for NMDA and (2S,3S)-3F D-72 at 25 °C.
pH
pKa = 1.77
pKa = 3.33
pKa = 9.94
70
Table 2.1 summarizes the pKa values of NMDA HCl compared to (2S,3S)-3F NMDA
HCl D-72. The fluorine substituent has lowered the pKa of both carboxylic acids and
the amine group as expected. The pKa1 of D-72 was lowered by 0.86 pKa of a unit
and pKa2 was lowered by 0.69 of a pKa unit, while the pKa3 was lowered by 0.28 of a
pKa unit. It would be expected that 3F-NMDA D-72 is a zwitterion form and overall
negative charge at neutral pH.
pKa1 pKa2 pKa3
NMDA.HCl 52 2.63 4.02 10.22
(2S,3S)-3F NMDA D-72 1.77 3.33 9.94
Table 2.1. Comparison of the pKa values of NMDA.HCl 52 and (2S,3S)-3F NMDA
HCl D-72.
52
D-72
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2.5 Biological Studies
2.5.1 Receptor assays with NMDA GluN1/N2A and GluN1/N2B.
Biological evaluation of the 3F-NMDA stereoisomers was performed at the Cellular
Neurophysiology and Pharmacology Centre for Integrative Physiology, at the
University of Edinburgh. The fluorinated NMDA HCl salts were tested on rat
NR1/NR2A and NR1/NR2B subunits of the glutamate receptor, expressed in Xenopus
laevis frog oocytes. A patch clamp assay was performed after 72 h injections. Two
electrode voltage clamp current recordings were set up in a solution containing 90
mM NaCl, 3 mM KCl, 10 mM HEPES, 0.5 nM BaCl2, 0.01 mM EDTA (10 μM) and 
0.05 mM glycine. The patch clamp analysis was carried out at 23 °C and pH 7.3.
Extra-cellular contaminants such as Zn2+ ions were chelated by adding 10 μM of 
EDTA. The current responses were recorded at a holding potential at –40 mV.
Responses and data acquisition were recorded by two electrode voltage-clamp
amplifiers and the responses by the agonists to the subunits were expressed from 0 to
1. The Emax below refers to the maximal current produced during the saturated
concentration of the agonist, while EC50 refers to the concentration of the agonist
required to produce 50 % of the response in Emax.
Based on the concentration response study (Figure 2.20) on the NR1/NR2A subunits,
the results clearly show that the (2S,3S)-3F NMDA HCl 72 stereoisomer is almost as
active as NMDA. In Figure 2.20, the maximum responses for NMDA 52 and
(2S,3S)-3F NMDA D-72 have been normalized relative to L-glutamate. NMDA gives
a response equivalent to 0.78 of that produced by glutamate whereas the
corresponding value for (2S,3S)-3F D-72 is 0.64 as shown in the Table 2.2. By
contrast, the unresolved enantiopure (-)- and (+)-3F-NMDA 73 were found to be
below the threshold of detection. A further analysis of the 3F-NMDA HCl
enantiomers with the GluNR1/NR2B subunit was conducted. In this case (Table 2.3),
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the relative maximum response of NMDA was found to be 0.96 and the (2S,3S)
3F-NMDA D-72 to be 0.54 as shown in Figure 2.21. Again, the resolved but not
configurationally assigned (-)-73 and (+)-73 were both below the detection threshold
and were essentially inactive.
Agonist Emax EC50
Glutamate 53 1.0 5.9 ± 0.3
NMDA 52 0.78 105 ± 6
(2S,3S)-3F NMDA D-72 0.64 150 ± 2
Table 2.2. Potency and relative efficacy of 3F-NMDA derivatives at GluN2A
NMDARs
Figure 2.20. Activities of (2S,3S)-3F NMDA 72 on NR1/NR2A subunit. Both (-)- and
(+)-3F NMDA 73 were found to be inactive.
GluN1/GluN2A
73
Agonist Emax EC50
Glutamate 53 1.0 4.0 ± 0.3
NMDA 52 0.96 48 ± 3
(2S,3S)-3F NMDA D-72 0.53 55 ± 1
Table 2.3. Potency and relative efficacy of 3F-NMDA derivatives at GluN1/N2B
NMDARs
Figure 2.21. Activities of (2S,3S)-3F NMDA 72 on NR1/NR2B subunit. Both (-)- and
(+)-3F NMDA 73 were found to be inactive.
GluN1/GluN2B
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The data was once again normalized relative to the maximum response for NMDA,
itself compared with that produced by a maximal concentration of glutamate. By this
measure, NMDA gives a response of 1 whereas the corresponding value for (2S,3S)
3F-NMDA 72 is 0.72. The other diastereoisomer series (-)-73 and (+)-73 gave very
low response as shown in Table 2.4.
GluN2A
Agonist @ 100 mM
GluN2B
Agonist @ 50 mM
NMDA 52 1.0 1.0
(2S,3S)-3F NMDA D-72 0.72 ± 0.03 0.45 ± 0.01
(+)-3F NMDA 73 0.009 ± 0.0009 0.0031 ± 0.0009
(-)-3F NMDA 73 0.001 ± 0.0005 Not detected (n.d).
Table 2.4. NMDA and 3F-NMDA potencies at the GluN2A and GluN2B receptor.
2.5.2 Two-electrode voltage-clamp (TEVC) analysis.
The relative potencies of the 3F-NMDA enantiomers were then compared by the
alternative two-electrode voltage-clamp (TEVC) analysis. The TEVC currents were
recorded from an oocyte expressing GluN1/GluN2A subunits. All agonists were
applied at 100 μM. NMDA 52 and (2S,3S) 3F-NMDA 72 each elicit large inward
currents as illustrated in Figure 2.22. By contrast, (-)- and (+)-3F NMDA 73 evoke
very low currents which are only resolvable on a higher (×100) gain setting (blue
traces)(Figure 2.22). All of the currents have been normalized to the response
produced by NMDA when it is applied at its EC50 concentration at either
GluN1/GluN2A or GluN1/GluN2B subunits (100 μM or 50 μM, respectively).   
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Figure 2.22 The TEVS analysis on 3F-NMDA stereoisomers. All the currents were
recorded from an oocyte expressing GluN1/GluN2A subunits.
The data extracted from that in Figure 2.22, but on an expanded scale to indicate the
low responses evoked by either (-)- and (+)-3F NMDA 73, is reformatted in
histogram form in Figure 2.23. Although the absolute stereochemistry of both (-)- and
(+)- 3F NMDA 73 could not be distinguished in this study, the biological assessment
has shown that these enantiomers and this relative stereochemistry do not act as
agonists, and thus achieve the wrong binding mode relative to NMDA.
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Figure 2.23. (a) TEVS analysis on 3F-NMDA enantiomers (b) All the currents were
recorded from an oocyte expressing GluN1/GluN2A subunits.
2.5.3 Binding conformation analysis of NMDA.
The above findings suggest that the (2S,3S)-3F NMDA D-72 is the sole stereoisomer
that can access the correct binding conformation for GluNR1/NR2A and
GluN1/NR2B NMDARs. The data also indicates that (-)- and (+)-3F NMDA 73
stereoisomers do not bind to the receptors. The preferred conformations of D-72 and
D-73 in solution were deduced to be those highlighted in the blue boxes (Figure 2.24)
based on Karplus relationship. Accordingly, the 3JHF coupling constants for the syn
H-C-C-F were known to be around 0-18 Hz whereas mixtures of syn- and anti-
periplanar relationship were found around 30.0 Hz. In this case, 3JHF of 72 was found
to be 29.9 Hz, indicating that the fluorine prefers a syn- or anti-periplanar orientation
to hydrogen. In addition, the 3JHH of 72 were found to be 2.0 Hz, suggesting that the
vicinal methylene hydrogens are gauche or close to 90 ° to each other. These data
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suggest that the major solution conformation in 72 is a folded conformation with the
carboxylates syn to each other, which means either conformation B or C is the
preferred solution conformation. The X-ray crystallography of Furukawa enables the
assignment of C (highlighted in blue) as the major binding conformation.
Conformation A is less relevant as this conformation will be high in energy, with the
fluorine anti to protonated amine. The same analysis was applied to 73 in which the
3JHF value shows a large coupling constant, about 26.0 Hz and a small 3JHH value 0.0
Hz, indicating that 73 prefers extended conformation A with the carboxylate groups
anti-periplanar to each other (highlighted in blue) as shown in the Newman projection
in Figure 2.24. Indeed, an X-ray crystal structure of 73 also has this extended
conformation (Figure 2.15).
Figure 2.24 The Newman projection of the 3F diastereoisomers. Coupling constants
of (i) D2O, 2J(H,F) = 44.0 Hz and 3J(H,F) = 26.0 Hz; (ii) D2O, 2J(H,F) = 47.9 Hz, 3J
(H,F) = 29.9 Hz.
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The biological results indicated that (2S, 3S)-3F 72 is inactive and (2S, 3R)-3F 73 is
not. The X-ray crystal structure of NMDA bound to the glutamate receptor (GluN2D)
(Figure 2.25) indicates that conformer C is the active binding conformation. The (2S,
3R)-3F 73 NMDA cannot easily adopt this conformation C as the fluorine and
NMeH3+ substituent would be anti-periplanar and high in energy relative to conformer
A and B. However, in the case of isomer (2S, 3S)-3F 72, conformer C, a major one in
solution can be accessed as the fluorine and NMeH3+ are gauche to each other, a
relative low energy conformation.
Figure 2.25 (i) The crystal structure of GluN2D in complex with
N-methyl-D-aspartate (NMDA) reported by Furukawa et al. (ii) NMDA is bound in
this folded conformation which was supported in this study.8
(i)
(ii)
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In solution, the minor solution conformation B is in equilibrium with C. In order to
trigger a response, the NMDA has to orientate conformation C. The active solution
conformation of NMDA 52 deduced from our study is consistent with the X-ray
structure study (Figure 2.26).
Figure 2.26 The active binding conformation was deduced to be conformation C
based on 3JHF values and biological assays.
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2.6 Conclusions
The (2S, 3S)-3-fluoro NMDA D-72 was successfully prepared from diethyl D-tartrate.
The (2S, 3R)- stereoisomer was prepared by separation of diastereoisomers generated
by reaction of a meso- epoxide with an enantiomerically pure amine, followed by
fluorination. Both the (2S,3R)- and (2R,3S)- enantiomers were prepared separately,
however assignment of the absolute configuration to each enantiomer could not be
unambiguously proven. The results of this study demonstrate that the active binding
conformation is the major solution conformation of (2S, 3S)-3F NMDA D-72. It is this
conformation that NMDA adopts when bound to GluNR1/2A and GluNR1/2B
sub-units. The other 3F-diastereoisomer cannot easily adopt that binding
conformation. This led to the conclusion that NMDA binds to the receptor with the
carboxylate groups gauche to each other, with the major solution acting as preferred
conformation. The study reinforces the recent finding of Furukawa et al, where they
solved an X-ray crystal structure of NMDA bound to the GluNR1/N2D subunits.8 The
study indicates that such comparative studies with fluorine stereoisomers of bioactives
can be utilized to explore the binding conformation of small molecules on proteins.
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Chapter 3: Fluorinated Cinacalcet analogues.
3.1 Introduction
Parathyroid hormone (PTH) is an important hormone produced by the thyroid gland.
Elevation of PTH level caused by abnormal calcium homeostasis is the main cause of
chronic kidney disease and in some cases can contribute to metabolic bone disease.1
Therapies such as administration of vitamin D sterols and phosphate binders have
been outlined to decrease PTH secretion. However, these treatments generate side
effects such as hypercalcemia and hyperphosphatemia.1 Lately, the calcium-sensing
receptor (CaSR) has emerged as a target of therapeutic interest to circumvent these
side effects.1
3.1.1 The calcium-sensing receptor (CaSR) in the parathyroid.
Accumulated research in structural biology has shown that the CaSR consists of seven
transmembrane (TM) helices. It is a member of G-protein-coupled receptor (GPCR)
family.2-6 The primary role of CaSR is to maintain constant blood Ca2+ levels by
regulating PTH secretion. PTH normalises the Ca2+ level in bone, kidneys and
intestines and it also regulates the vitamin D receptor (VDR).
When Ca2+ levels are high (hypercalcemia), parathyroid cell proliferation and PTH
gene expression are suppressed, and the VDR is then upregulated. In addition, high
Ca2+ levels are inhibited by calcitonin (CT) and the 1,25 (OH)2D3 production
decreases. In response to the high calcium level, the activity of bone-resorbing
osteoclasts is suppressed. As a consequence, the net Ca2+ level is normalized by
reduction of Ca2+ release from bone. At the renal tubular level, an increase of Ca2+
reduces calcium reabsorption in both cortical thick ascending limb (cTAL) and distal
convulated tubule (DCT) into the blood plasma.7-9
Fi
by
3.
Th
ha
lig
tri
m
bi
cla84
gure 3.1 Calcium homeostasis regulated in three organs; kidney, bone and intestine,
transport of the calcium in or out of the extracellular fluid (ECF).10
2 Allosteric modulators and CaSR ligands.
e function of the CaSR is mediated by exogenous ligands. Two types of ligands
ve been recognized, namely orthosteric and allosteric modulators. Orthosteric
ands are capable of activating the CaSR directly. Examples are divalent and
valent cations, such as the Ca2+, Mg2+, Al3+, Ni2+ and Ba2+. By contrast, an allosteric
odulator is only capable of activating the receptor if it is accompanied by the
nding of primary orthosteric ligands. Orthosteric and allosteric modulators are
ssified as type I and type II agonists, respectively.
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3.2.1 Orthosteric ligands (Type I agonists).
Orthosteric ligands (types I agonists) of the CaSR have been studied extensively and
it is generally agreed that these exogenous ligands offer more benefit than harm.
Among these are metal ions strontium and aluminium (Sr2+ and Al3+). Studies on the
effect of Sr2+ has shown that it is effective in osteoporosis treatment and is widely
used for this purpose.11 Sr2+ activates the CaSR and thereby promotes osteoblasts in
bone formation. By contrast, osteoclasts promote brittle bone or bone resorption of
Ca2+. Osteoblasts and osteoclasts are involved in physiology processes that control
bone tissues. In hypercalcemia, bone resorption is inhibited controlling the break
down of the bone. As a result, blood calcium levels are restored as Ca2+ is no longer
transferred from bone to the blood. Sr2+ also works by stimulating the production of
osteoprotegerin from osteoblasts, thus inhibiting the formation of osteoclasts from
preosteoclasts in a similar manner.12-14 However, orthosteric ligands (type I agonists)
can have negative side effects.15 The aminoglycoside antibiotics, namely neomycin
111, gentamicin 112 and tobramycin 113 (Figure 3.2) were reported to increase Ca2+
levels upon binding to CaSR and were responsible for renal toxicity.15
Figure 3.2 The aminoglycoside antibiotics are type I orthosteric agonists of the CaSR.
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Polyamines are known to activate the CaSR and have been demonstrated to inhibit
PTH secretion. These cationic compounds (spermine 114, spermidine 115 and
putrescine 116, Figure 3.3) inhibit PTH secretion. Further biological evidence has
shown that spermine 114 has other physiological roles, such as the regulation of
gastrointestinal epithelia function and stimulation of gastrin release in stomach
through activation of the CaSR.16-17
Figure 3.3 Polyamines belong to the Type I orthosteric agonists of the CaSR.
3.2.2 Allosteric modulators (Type II agonists).
The phenylalkylamine drugs including Cinacalcet 117, NPS R-568 118, NPS R-467
119 and calindol 120 (Figure 3.4) are allosteric modulators displaying calcimimetic
effects. These compounds are known to inhibit secretion of PTH in patients with
hyperparathyroidism through binding to an allosteric site of the CaSR. The
calcimimetics influence Ca2+ release leading to the inhibition of PTH secretion.
Cinacalcet 117 emerged as a more potent allosteric modulator than NPS R-568 118
and NPS R-467 119. Cinacalcet 117 is undergoing clinical trials for treating
parathyroid cancer patients.18 The calcimimetic Calindol 120 is another in this series
developed for the same purpose with a similar structure but with an indole ring.19
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Figure 3.4 Phenylalkylamines type II allosteric modulators CaSR.
Compound 121 acts opposite to the calcimimetics but also binds the allosteric site of
the CaSR.20 This compound is a calcilytic, or a negative allosteric modulator. It
interacts by elevating PTH secretion. This negative allosteric modulator recently came
to attention due to its potential for osteoporosis treatment. Furthermore, 121 has been
demonstrated to regulate PTH levels and thereby emerges as a potential lead candicate
for drug development. Another calcilytic which has been identified recently is Calhex
231 122. As a class, their mechanism of action of these drugs involves binding to an
CaSR allosteric site, the location of which is still under investigation.
Figure 3.5. The calcilytics belong to the type II CaSR allosteric modulators.
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3.3 Binding conformation of calcimimetic and calcilytics on the
CaSR.
Some effort has gone into understanding the binding of the phenylalkylamines,
including the calcilytic compounds to CaSR. A structural feature common to both
NPS R-568 118 and NPS 2143 121 is the presence of a phenylalkyl amine. The amine
is protonated and positively charged at physiological pH. Recent homology modeling
using the crystal structure of G-protein coupled receptor bovine rhodopsin bRho as a
template, has displayed that the both 118 (calcimimetic) and 120 (calcilytic) bind to
the 7TM of CaSR as illustrated in Figure 3.6.21 Furthermore, this finding has also
indicated that the protonated amine forms an ionic interaction with the Glu 837
residue. This further implies that the location of binding for calindol 120 and NPS
R-568 118 is the same, however their unique binding modes at this site are different.
This homology data remains speculative and the working hypothesis requires to be
verified by experimental data. In the most recent study from Bristol-Meyers Squibb,
“BMS compound 1” 125 was found to stimulate PTH secretion when administrated
orally.22 This compound emerges as a potential drug for the treatment of osteoporosis.
Interestingly, 125 was found to have a different binding site compared to NPS 2143
121 and other phenylalkylamines. The binding does not appear to involve the Glu837
residue, instead deletion of the Ile841 residue eliminated the potency of 125.23 Further
identification of improved chemical entities which are capable of modulating the
agonism and antagonisim on the CaSR is needed. This project is focused on exploring
the binding mode of cinacalcet on the CaSR by comparative and stereospecific C-F
bond modification to generate two diastereoisomers 123 and 124.
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Figure 3.6. Homology modelling for NPS R-568 118 indicates that the N-H forms a
hydrogen bond with Glu837.24
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3.4 The pentafluorosulfanyl group (SF5), a new substituent for
medicinal chemistry.
The physical properties and electronegativity of the SF5 group has attracted a lot of
attention in recent years. The interest in the SF5 group is derived from its physical
properties, which include high chemical resistance, thermal stability, electron
withdrawing nature and hydrophobicity which make it an attractive substituent for
modifying pharmacokinetic properties.25 Moreover, these combined properties
suggest that it may be an alternative to the trifluoromethyl group, a widely used
substituent in pharmaceutical development.26 In terms of size, the pentafluorosulfanyl
group is slightly smaller than the tert-butyl group, but it is clearly larger than the
trifluoromethyl group.29 Pentafluorosulfanyl is more electronegative than the trifluoro
group, 3.65 D vs. 3.36 D in terms of electronegativity.17
There are a limited number of examples involving incorporation of SF5 group into
bioactive molecules. This is due to the limited number of SF5 building blocks. P. Wipf
et al., reported the synthesis of analogues of SF5 mefloquine.27 Mefloquine 126 is an
orally administrated drug used for the treatment of malaria. However, its application
has been hindered recently by many side effects such as depression, anxiety,
hallucination and seizures. In this work, efforts have been carried out to re-engineer
the molecule by substituting the CF3 group to different positions, and placing SF5 on
the aromatic ring. Direct comparison of the SF5 analogues to the original mefloquine
in mammalian cell lines (Pf 235) showed the IC50 of 127 and 128 to be more potent,
than 126 (9.8 and 10.0 vs. 18 ng/mL respectively). Analogues 127 and 128 were more
potent against some cell lines, suggesting that the CF3 and SF5 group could be
interchangeable, sometimes to advantageous effects.27
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Figure 3.7.Antimalaria activity exhibited by SF5 and CF3 analogues of mefloquine.
Drug discovery programmes targeting modifications of fluoxetin (rac)-131,
fenfluramine (rac)-132 and norfenfluramine (rac)-133 (Figure 3.8) obtained an
interesting outcome when the trifluoromethyl group was replaced by the
pentafluorosulfanyl group. This led to enhanced potency against the
5-hydroxytryptamine (5-HT) receptor.28 Fluoxetin (rac-131) and fenfluramine
(rac-132) were first introduced as clinical agents in 1974 as selective serotonin
reuptake inhibitors. The 5-HT receptors are well known to control human physicology.
Fluoxetin is the market leaders with profit margins of more than $3 billion per year,
while fenfluramine (rac-132) and norfenfluramine (rac-133) have been withdrawn
from the drug market due to detrimental side effects on appetite.
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The pentafluorosulfanyl analogues of fenfluramine (rac)-135 and norfenfluramine
(rac)-136 were prepared from pentafluorosulfanylbenzene building blocks.28 Binding
and inhibition assays showed that both (rac)-135 and (rac)-136 have ten-fold
increased affinity for the 5-HT6 receptor. More strikingly the pentafluorosulfanyl
analogues showed binding selectivity between different receptor subtypes.
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e 3.8. Fluoxetin (rac)-131, fenfluoroamine (rac)-132, norflenfluroamine
(rac)-133 and some pentafluorosulfanyl analogues.
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3.5 Aims of this project
The study can be divided into two parts. The first objective involved the synthesis of
the individual diastereoisomer (2R,1’R)-123 and (2S,1’R)-124 of fluoro cinacalcet
HCl to study the relative efficacy of these compounds on the calcium sensing receptor
as shown in Figure 3.9. This concept is similar to that described in the 3-fluoro
NMDA research discussed in the previous chapter. It is anticipated that the
C-F---NH3+-C interaction will favour a gauche conformation with a low population of
anti conformation in solution. In order to explore the preferred binding conformation
of Cinacalcet HCl 117, assays and relative potency of these fluorinated
diastereosiomers should allow an assessment of the preferred binding conformation,
based on our understanding of fluorine chemistry.
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Figure 3.9 Cinacalcet and the two fluorinated diastereoisomers 123 and 124.
second objective will focus on the synthesis of a pentafluorosulfur 3’’-(SF5-)
ogue of Cinacalcet as shown in Figure 3.10. It is anticipated that replacing CF3-
F5- should increase the lipophilicity of this substituent.
Figure 3.1
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0 3’’-SF5-Cinacalcet HCl 137 a synthetic target.
he synthesis of Cinacalcet.
reports have appeared on the synthesis of Cinacalcet. Most of
ductive amination with sodium cyanoborohydride or sodium
An example of this is illustrated in Scheme 3.0 using
condensed with arylethylamine followed by a one-pot
0 Previous synthetic study on the route to 117.29
Alternatively, the synthesis of 117 has been assessed from
3’-(trifluoromethyl)cinnamic acid 140. Successful hydrogenation on the olefinic
carbon of 140 in the presence of palladium hydroxide and hydrogen, gave 141, which
could be coupled with (R)-1-(1-napthyl)ethylamine 142 to generate amide 143. Acid
chloride or peptide coupling reagents have been used to activate the carboxylic group.
It has been reported the amide can also be generated via direct condensation of the
carboxylic acid with the amine without any solvent, as shown in Scheme 3.1.30
Removal of the amide carbonyl with sodium borohydride in the presence of boron
trifluoride and then recrystallization afforded 117.95
Scheme 3.1 Direct condensation of carboxylic acid 141 with amine 142. Reagents and
conditions: a) Pd(OH)2/C, H2 (3-4 bar), 40-60 °C, quantitative; b) toluene, NaOH,
quantitative; c) 142, 140-150 °C, 95%, d) NaBH4, BF3.THF, THF.diglyme, 45-60 °C,
2. toluene, HCl, 95%; e) MeOH/H2O, 95%.
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3.7 Results and Discussion.
3.7.1 Retrosynthesis of fluoro Cinacalcet HCl.
The synthetic approach to cinacalcets 123 and 124 was explored as shown in Scheme
3.2 This route contains two important steps which involve a Macmillan asymmetric
fluorination followed by a reductive amination.30 The retrosynthetic analysis indicates
that both (2R,1’R)-123 and (2S,1’R)-124 could be accessed by displacement of the
triflates of (R)-149 and (S)-149 with (R)-1-(1-napthyl)ethylamine 142. These triflates
could be prepared from alcohols (R)-148 and (S)-148. The fluoro alcohol (R)-148 and
(S)-148 could reasonably be obtained from aldehyde 146 by a Macmillan fluorination
protocol, involving reductive amination with (R)-1-(1-napthyl)ethylamine 142 and
then treatment with sodium borohydride or lithium aluminium hydride in a one pot
reaction. The different enantiomers can be achieved by utilizing different enantiomers
of the Macmillan organo-catalyst (R)- or (S)-150. Finally, aldehyde 146 can be
prepared as previously described in three steps from 3’-(trifluoromethyl)cinnamic
acid 140. The envisaged route towards (2R,1’R)-123 is outlined in Scheme 3.3.
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heme 3.2 Retrosynthetic routes of the two fluorinated diastereoisomers of
Cinacalcet.
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Scheme 3.3 Proposed synthesis of 2F-(2R,1’R)-123.98
Scheme 3.4 Proposed synthesis of 2F-(2S,1’R)-124.
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3.7.2 Synthesis of (2R,1’R)-2F Cinacalcet 123.
The successful preparation of 146 involved three individual steps starting from
hydrogenation of olefin 140. Further reduction of carboxylic acid group gave alcohol
145. Oxidation of 145 by a Dess-Martin periodinane reaction generate aldehyde 146,
which was then subjected to a Macmillan asymmetric fluorination.31 Accordingly, 146
was treated with 2.5 equivalent of NFSI and 10 % mol of (+)-Macmillan catalyst
(5R)-150 in THF/isopropanol (9:1) at -15 °C. This solvent combination plays a
significant role due to the polar protic nature of isopropanol, which can solvate the
fluoride ion. Another factor that influences the formation of 147 is the temperature
which was kept around –15 °C to obtain an optimum yield of the mono-fluorinated
aldehyde.
The reaction was stirred at low temperature and the production of (R)-147 was
monitored by GC-MS until the consumption of the starting material (> 99%). Most of
the substrate is converted to the mono-fluorinated aldehyde (R)-147, however about
5-10 % of the difluoro aldehyde 151 was recovered from the reaction. Measurement
of the enantiomeric excess (ee) was carried out by mixing both (R)- and (S)-147
followed by chiral phase GC-MS analysis. The chromatogram is shown in Figure
3.13. Clearly, the mixture of both (R)- and (S)-147 shows two distinctive signals
which are consistent with the two enantiomers injected into GC-MS. The
enantiomeric excess of (R)-147, measured by chiral phase GC-MS, was found to be
99%ee (Figure 3.11). Subsequently, the reduction of fluoro aldehyde (R)-147 was
carried out with lithium aluminium hydride. The difluoro alcohol 152 contaminant
could be separated by careful chromatography to afford (R)-148 in a reasonable yield
(80%). The proposed mechanism for the formation of (R)-147 is depicted in Scheme
3.5. The same procedure was then applied to the synthesis of (S)-147 in which the
Macmillan catalyst (5S)-150 was employed and the reaction was again monitored by
the GC-MS. The resultant analysis is shown in Figure 3.12. The enantiomeric excess
of the resultant (S)-147 was measured also to be 99%ee by chiral phase GC-MS.
Scheme 3.5 Proposed intermediates for the Macmillan asymmetric fluorination.40100
Scheme 3.6. Reagents and conditions: a) NFSI (2.5 equiv),
(5R)-(+)-2,2,3-trimethyl-5-benzyl-4-imidazolidinone dichloroacetic acid salt (10%
mol), THF/Isopropanol (9:1), - 15 °C; b) LiAlH4 (2.0 equiv), - 15 °C, 80%.
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Figure 3.13 Chiral phase GC chromatogram of a mixture of (R)- and (S)-147.Figure 3.14 19F
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With (R)-148 in hand, a conversion to the triflate was required. Accordingly, (R)-148
was transferred through cannula into a reaction mixture containing triethylamine,
DMAP and trifluoromethanesulfonic anhydride. The reaction was left stirring under
argon for 16 h. Work-up and concentration gave a very good conversion to product as
indicated by 1H-NMR. This product was used for the subsequent step without further
purification. The final step involved the displacement of the triflate group of (R)-149
with (R)-1-(1-napthyl)ethylamine 142 to generate the (2R,1’R)-123 as shown in
Scheme 3.7. By this method, the first fluorinated Cinacalcet diastereoisomer was
obtained in a good yield (95%). The second diastereoisomer was obtained after
repeating the same procedure for (S)-147. In order to study the diastereoisomeric
relationship between (2R,1’R)-123 and (2S,1’R)-124, the overlay of their 1H- and 19F
NMR spectra shown in Figure 3.15 and Figure 3.16 respectively. Indeed, the signals
for the methylene and methyl groups are shifted slightly when compared to each other,
consistent with a set of diastereosiomers.
Schem
(CF3103
e 3.7 Synthesis of (2R,1’R)-fluoro Cinacalcet 123. Reagents and conditions: a)
SO2)2O (1.2 equiv), Et3N (2 equiv), DMAP (10% mol), 0 °C- RT, 16 h, 76%. b)
(R)-1-(1-napthyl)ethylamine (1.2 equiv), toluene, 140 °C, 95%.
Figure 3.15.
Figure
H2
N
F
F3C
F3C
F3C
(2R,1’R)-1
(2S,1’R)
-Ar-H
-Ar-HA set of diaseteoisomers o
of (2R,1’R)-1
3.16. Overlay of the 19F-N
and a mixture of
Cl-
H2
N
F
F3C
Cl-
(2R,1’R)-123
H2
N
F
F3C
Cl-
H2
N
F
Cl-
H2
N
F
23
-124
(2S,1’R)-124
-CH3
2 ×-CH2-CHF
-C
-CHMebserved by the overlay of 1H-NMR spectrum
23 and (2S,1’R)-124.
(2S,1’R)-124 -CH3
2 ×-CH2HF CHMe10
MR
bot
H2
N
F
F3CCl-
Cl-4
spectra of (2R,1’R)-123 and (2S
h diastereoisomers.
(2R,1’R)-123-,1’R)-124
The diastereomeric purity was determined by 19F-NMR as shown in Figure 3.16.
From the 19F NMR analysis, it is very clear that only one set of peaks is observed in a
single spectrum. The lower spectrum shows the mixture of diastereoisomers
(2R,1’R)-123 and (2S,1’R)-124. The 19F NMR analysis indicates a very high
diastereomeric ratio for each of these end-products. Subsequently, a suitable crystal of
the (2R,1’R)-123 was obtained from crystal structure analysis. The X-ray crystal
structure confirms the absolute configuration as (2R,1’R)-123. A dihedral angle of
53.0 ° was measured for the C-F---N+-C angle, consistent with a gauche conformation.
Examination of the X-ray crystal structure of (2R,1’R)-123 reveals that the fluorinated
Cinacalcet adopts a similar alkyl chain conformation to the non-fluorinated
Cinacalcet32 as showed in Figure 3.17.
Figur
(i)
(105
e 3.17 Comparison of the X-ray crystal structure of (i) Cinacalcet32 117 and (ii)
(2R,1’R)-123.
ii)
3.7.3 Synthesis of Cinacalcet HCl 117.
A synthesis of Cinacalcet was carried out as a control for biological assessment. The
synthesis followed the literature protocol of Wang et al.33 Carboxylic acid 140 was
used as the starting material. The synthesis was similar to that previously described,
except that the last step involved amination with simultaneous reduction, as
summarized in Scheme 3.8. The 1H NMR spectrum of Cinacalcet is shown in Figure
3.18 and was identical to that reported for Cinacalcet HCl 117.106
Scheme 3.8. Synthesis of Cinacalcet. Reagents and conditions: a) Pd/C, H2, EtOH, RT,
2h, 98 %; b) LiAlH4 (1.5 equiv), THF, 75 °C, 1 h, 95%; c) DMP (2 equiv), DCM, RT,
1 h, 80 %; d) 1. (R)-1-(1-napthyl)ethylamine, RT, 5 h; 2) NaBH(OAc)3, RT; 3) HCl
ether, methanol, 80%.
Figure 3.18 1H NMR spectrum of synthetic Cinacalcet 117 (CDCl3).
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3.8 Solution conformation analysis of the fluorinated Cinacalcet
diastereosiomers.
The coupling constants from 1H- and 19F- NMR offer information on the solution
conformation for the 2F-Cinacalcets. The NMR simulation software DAISY which is
part of the processing package in Topspin proved to be useful as it can be employed to
simulate the 2J, 3J H-H and H-F coupling constants. The coupling constants allow an
assessment of the conformation of these molecules in solution. Accordingly, the
approximate coupling constants associated with the conformation of (2R,1’R)-123
were entered into the DAISY program and the software refined the values. After
several iterations, the software generates a good match between the simulated and
experimental spectra. The coupling constants retrieved from this process were found
to match the 1H- and 19F- NMR spectra recorded at 500 MHz as shown in Figure 3.20
and Figure 3.21. The same analysis was conducted on (2S,1’R)-124 (Figure 3.22 and
Figure 3.23), the coupling constants in each analysis are displayed in Table 3.0 and
3.1.
Figure 3.19 illustrates the Newman projections for both (2R,1’R)-123 and
(2S,1’R)-124 and the dihedral angles deduced from the DAISY program were
consistent with the angle of fluorine to adjacent protons. In Figure 3.19 (i), the 3JHF
value of the fluorine cis to H4 was found to be 17.5 Hz, consistent with a small
dihedral angle and the coupling constant of fluorine anti to the H3 was found to be a
large value, 30.8 Hz. Similarly, Figure 3.19 (ii) displayed that the the fluorine cis to
H2 3JHF value was found to be 20.9 Hz, whereas the the anti relationship of fluorine to
H1 was 31.0 Hz.
The same analytical procedure was applied to (2S,1’R)-124 and the Newman
projection is illustrated in Figure 3.19 (iii) and (iv). The data is consistent with the
two fluorinated diastereoisomers adopting an extended conformation in solution with
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the amine anti to the phenyl group (R2) bearing a trifluoromethyl group. The solution
conformation deduced from this experiment is also reinforced by the X-ray crystal
structure of the (2R,1’R)-123, which shows an extended conformation in the solid
state (Figure 3.17).
Figure 3.19. (a) Newman projection of the (2R,1’R)-123 (2S,1’R)-124 deduced from
DAISY program. (b) The preferred conformation of (2R,1’R)-123 and (2S,1’R)-124 in
solution phase.
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m of (2R,1’R)-123 at 500 MHz (CD3OD at 25 °C).
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m of (2R,1’R)-123 at 500 MHz (CD3OD at 25 °C).
Figure 3.22 The simulat
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ed (top spectrum) and experimental (bottom spectrum) 1H
of (2S,1’R)-124 at 500 MHz (CD3OD at 25 °C).
ed (top spectrum) and experimental (bottom spectrum) 19F
of (2S,1’R)-124 at 500 MHz (CD3OD at 25 °C).
H1 H2 H3 H4 H5
F 31.03 20.87 30.77 17.51 -49.85
H1 -12.60 0 0 3.03
H2 0 0 6.90
H3 -14.46 4.20
H4 8.62
Table 3.0. Coupling constants of (2R,1’R)-123 extracted from the simulated NMR
spectrum.
H1
F 12.46
H1
H2
H3
H4
Table 3.1. Coupling co111
H2 H3 H4 H5
34.53 19.49 29.35 -50.52
-13.73 0 0 9.79
0 0 1.79
-15.86 8.24
3.91
nstants of (2S,1’R)-124 extracted from the simulated NMR
spectrum.
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3.9 Synthesis of 3’’-SF5-Cinacalcet HCl 137.
As part of our programme exploring Cinacalcet anaogues, we were interested to
explore the substituent effect of a Cinacalcet analogue bearing a pentafluorosulfur
(-SF5) group in place of the trifluoromethyl (-CF3) group. The proposed synthetic
route towards this 3’-SF5-Cinacalcet analogue 137 is outlined in Scheme 3.9.
Scheme 3.9 The proposed synthetic route to 3’’-SF5-Cinacalcet HCl 137.
The synthesis of benzylbromide 154 proved to be straightforward following a
published protocol.34 This involved the treatment of alcohol 153 with PBr3 in THF at
room temperature. After the starting material was consumed, benzyl bromide 154 was
purified by chromatography and was recovered in good yield (76%). The next
reaction, which involved nucleophilic displacement of the bromide with diethyl
malonate and sodium hydride at –78 °C, was followed by 1H-NMR. After all the
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starting material was consumed, the crude mixture was treated with NaOH (6 M) in
EtOH and the reaction mixture was heated under reflux. The saponification product
was then treated with concentrated HCl (4 M) to mediate a decarboxylation of the in
situ formed malonic acid. Work-up was carried out with sodium hydrogen carbonate
and the pH was adjusted to pH=3 to enable the products to be extracted into ethyl
acetate. Purification by careful chromatography gave the desired carboxylic acid 155.
Scheme 3.10. Synthesis of carboxylic 155 from alcohol 153. Reagents and conditions:
a) PBr3 (1.2 equiv), THF, RT, 3 h, 76%; b) 1. NaH (1.0 equiv), THF, CH2(CO2Et)2
(1.0 equiv), - 78 °C- RT, 16 h; 2. NaOH 6M, EtOH, reflux, 16 h; 3. HCl 4 M, reflux
16 h, 50%.
With carboxylic acid 155 in hand, it was treated with lithium aluminium hydride to
generate alcohol 156. As anticipated, the reduction proved to be a straightforward
reaction and after work-up, 156 was obtained as a clear oil. This product 156 was
used without further purification.
Scheme 3.11 Preparation of alcohol 156. Reagents and conditions: a) LiAlH4 (1.5
equiv), THF, reflux, 90%.
It was necessary now to oxidize alcohol 156 to an aldehyde. A Dess-Martin oxidation
approach was carried out. Column chromatography of the oxidation product afforded
157 in a good yield (90%) and this aldehyde was then treated with
(R)-1-(1-napthyl)ethylamine 142 in THF for 5 h followed by reductive amination. As
expected, 157 was all converted into a single product, as indicated by TLC. Column
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chromatography afforded 137 as a free base, which was then dissolved in methanolic
HCl in diethyl ether to afford the 3’’-SF5-Cinacalcet HCl salt 137. The 1H NMR
spectrum of 137 is shown in Figure 3.24.
Scheme 3.12 Synthesis of 137 from 157. Reagents and conditions: a) DMP (1.5
equiv), DCM, RT, 1 h, 90 %; b) 1. (R)-1-(1-napthyl)ethylamine (1.2 equiv), THF, RT,
5 h; 2. NaBH(OAc)3, RT; 3) HCl ether, methanol, 90%.
Figure 3.24. The 1H NMR spectrum of 137 in CDCl3.
The 1H-NMR spectrum of 137 has three signals for three sets of methylene protons
(2.69 ppm, 2.47 ppm and 2.19 ppm) which corresponded to H1, H3 and H2 respectively.
Closer examination of these methyene protons by 1H-1H COSY-NMR (Figure 3.25)
confirms that H2 is located between H1 and H3. Analysis of the 1H-HMBC spectrum
(Figure 3.26) indicated that H3 has a crosspeak with the aromatic carbons at 125.4
ppm which confirms that H3 is located between H2 and the phenyl group.
Ar-H
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2×H1
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-CH3
F5S
H2
N
Cl-
H2
H3 H1
137
115
Figure 3.25 The 1H- 1H COSY NMR of 3’’-SF5-137 in CDCl3.
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Figure 3.26 1H-HMBC NMR spectrum of 3’’-SF5-137 in CDCl3.
The 13C NMR analysis (Figure 3.27) of 137 reveals three methylene carbons at 27.3
ppm, 32.6 ppm and 45.4 ppm. Other signals such as that at 21.3 ppm correspond to be
the methyl group. The methine carbon is assigned to 53.5 ppm and the aromatic
carbons have signals at 121.2 ppm to 141.0 ppm. The 2D-HSQC spectrum (Figure
3.28), indicates that H1 has a crosspeak to the methine carbon at 45.4 ppm.
Furthermore, the H3 and H2 methylene groups are found to have crosspeaks to carbons
at 32.6 and 27.3 respectively, suggesting that the H2 methylene group is located in
between H1 and H3, with H3 assigned to be the aryl carbon, adjacent to that bearing
the SF5 group.
2×H3
Figure 3.27 The DEPT 13C NMR spectrum of 3’’-SF5-137 in CDCl3.117
Figure 3.28 The 2D-HSQC NMR spectrum of 3’’-SF5-137 in CDCl3.
H2
H3
H1
C3
C2
C1
19F NMR spectrum (Figure 3.29) of 137 is shown to have two different fluorine
populations with signals at 62.1 ppm and 84.8 ppm. Both signals correspond to the
fluorines in the SF5 group. The signal at 62.1 ppm integrated as four and is attributed
to all four of the equatorial fluorines coupled to the axial fluorine, to produce a
doublet. The signal at 84.8 ppm, which integrated as one is assigned to the axial
fluorine, coupled to all four equatorial fluorine and thus the multiplicity is a quintet.
Figure 3
4×Feq118
.29 The 19F NMR spectrum of 3’’-SF5-137 showing the axial and equatorial
fluorines.
Faxial
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3.10 Biological Result
3.10.1 Biological Assessment of the Fluorinated Cinacalcet Analogues with CaSR.
All the calcimimetics 117, 123, 124 and 137 was assessed by using a calcium imaging
technique. The free intracellular calcium was visualized by binding to a fluorescent
compound, namely Fura-2. Visualization was achieved by exciting the cells at
different wavelengths of light, at 340 and 380 nm and the ratio between those two
wavelengths is directly correlated with the amount of intracellular calcium. In this
experiment, stimulation of the CaR was achieved by using a concentration of 100 nM
for all the calcimimetics in a physiological buffer. Each of these calcimimetics was
left to stimulate the cells for 2 min and subsequently the cells was left for another 5
min to restore to their normal calcium levels. At the end of each experiment, the
calcimimetic was added into the cells as a positive control to ensure that the cells
were still responding.35
The graph in Figure 3.30 represents the response for all four calcimimetics fitted into
a single plot. On the Y-axis the 340/380 ratio is plotted and on the X-axis the
calcimimetics concentration in micromolar is shown. The EC50 for each compound is
calculated from each individual graph and depicted in Table 1.3.
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Figure 3.30 Overall dose-response curves represent the all four calcimimetics
(117,123, 124 and 137) response towards the calcium visualization excited at 340 and
380 nm.
Cinacalcet HCl
117
SF5-Cinacalcet
HCl 137
(2S,1’R)-2F
Cinacalcet HCl
124
(2R,1’R)-2F
Cinacalcet HCl
123
Maximum
response
4.791 3.646 3.573 4.040
EC50 (µm) 0.13 0.12 0.16 0.14
Table 3.2 The maximum response and EC50 of the fluorinated and non-fluorinated
calcimimetics obtained from individual experiments.
The SF5-3’’-Cinacalcet 137 give a comparable EC50 similar to that of Cinacalcet HCl
117, around 0.13 to 0.12 µm. This means that the substitution of CF3- by SF5- group
in Cinacalcet 117 can be interchangeable, and this does not lead to decrease in
bioactivity as shown in Table 3.2. In contrast, the fluorinated calcimimetics
(2R,1’R)-2F 123 and (2S,1’R)-2F 124 were found to have lower activity compared to
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the control 117. This could be explained in terms of our understanding of fluorine
chemistry. Firstly, it is well-understood that the introduction of fluorine will decrease
the pKa of a β- amine group. In this case, the reduced of activities in both fluorinated
calcimimetics 123 and 124 is perhaps understandable. Secondly, the syntheses of
these diastereoisomers will either reinforce or destabilize the active binding
conformation of Cinacalcet 117.14,17 Therefore, the difference in terms of EC50
suggests a preferred binding conformation in solution. From the Newman projection
in Figure 3.31, this conformation for 117 was deduced to be conformation A. Only
conformation A can be accessed by both diastereoisomers 123 and 124, with the alkyl
group extended to each other. Conformation C would be less able to achieve this
conformation due to the loss in C-F and C-N+ stabilization.
Figure 3.31 The preferred binding conformation of Cinacalcet HCl 117 in solution as
represented by Newman projection.
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3.11 Conclusion:
Diastereoisomers 123 and 124 of 2F-Cinacalcet HCl have been successfully prepared
from 3’-(trifluoromethyl)cinnamic acid in high diastereoisomeric ratio. The 3’’-SF5-
derivative 137 of Cinacalcet is also prepared in conjunction with this study.
3’’-SF5-137 was accessed from pentafluorosulfanyl benzyl alcohol. The major
solution conformation of the 2F-Cinacalcet diastereoisomers have been assessed
based on the coupling constants that were simulated by DAISY Topspin. They were
found to be in an extended conformation for both of the 2F-Cinacalcet HCl
diastereoisomers 123 and 124. In the biological assessment, the relative potency of the
non-fluorinated Cinacalcet 117 and fluorinated Cinacalcets diastereoisomers 123 and
124 were studied in CaR. It was found that both fluorinated Cinacalcets 123 and 124
were active at a nano-molar scale, however were slight lower potency compared to the
non-fluorinated Cinacalcet 117. It is therefore concluded that in solution, Cinacalcet
binds in an extended conformation with the alkyl chain anti-periplanar to each other.
This was also supported by a suitable crystal of (2R,1’R)-2F Cinacalcet 123 and 3JHF
values generated for both 123 and 124 by Topspin Daisy analysis, in which both
fluorinated diastereoisomers adopt an extended alkyl chain in solution. The biological
assessment of 3’’-SF-Cinacalcet 137 revealed that the SF5- substituent has a similar
potency to Cinacalcet 117. The result of this study proves that both substituents can be
interchangeable and that the SF5 group can be used as a bioisosterase for CF3 in
medicinal chemistry.
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Chapter 5. Experimental Section
5.1 General methods
5.1.1 Reagents, solvents and reaction conditions.
All reagents used in synthesis reactions were obtained from commercial supplies as
synthetic grade reagents and were used without further purification. Dry
tetrahydrofuran, dichloromethane, toluene and diethylether were obtained from the
Solvent Purification System MB SPS-800. Isopropyl alcohol was distilled from CaH
before used. All moisture sensitive reactions were carried out under a positive
pressure of nitrogen in standard vacuum lines. All glassware was flame dried or
oven-dried at 140  C. Reaction temperatures of 0 C were obtained using ice or water
bath. Reactions of -15 C to –78 C were obtained by using an isopropyl alcohol bath
together with cooling apparatus LP Technology RP-100-CD. Reactions requiring
heating were achieved on a heating block with a thermostatted thermometer. Organic
extracts were dried over MgSO4. RT refers to ambient temperature.
5.1.2 Chromatography and mass spectroscopy.
Column chromatography was performed using Apollo Scientific Ltd. silica gel 60
(43-63 micron). Thin layer chromatography (TLC) was performed using
Macherey-Nagel Polygram Sil G/UV254 plastic and aluminium plates. Visualization
was achieved by inspection under UV light (255 nm) or by use of potassium
permanganate stain or molybdenum-based stain. High resolution and low resolution
mass spectra were recorded using a Micromass LCT-TOF mass spectrometer using
ES ionization in + ve and – ve mode, sometimes the CI was used if inadequate.
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5.1.3 Nuclear magnetic resonance spectroscopy (NMR)
NMR spectra were recorded on either Bruker AV-300 (1H at 300.06 MHz, 13C at
75.45 MHz), 19F at 282.34 MHz), or Bruker AV-300 (1H at 300.13 MHz, 13C at 75.48
MHz) or Bruker AV-500 (1H at 499.90 MHz, 19F at 470.33 MHz). Samples were
prepared either in deuterated chlorofrom, deuterated methanol or deuterium oxide.
Chemical shifts  are reported in parts per millions (ppm) and quoted relative to
internal standard Me4Si for 1H and 13C and external standard CFCl3 for 19F. Coupling
constants (J) are given in Hertz (Hz) and the splitting patterns described as: singlet-s,
doublet-d, triplet-t, multiplet-m, doublet of doublets-dd or a broad doublet-brd.
Spectroscopic data were assigned based on the combination of one- and
two-dimensional experiments (COSY, HSQC and HMBC).
5.1.4 Gas chromatography
GC-MS analysis was carried out using an Agilent 6890 gas chromatograph coupled to
a 5973 N mass spectrometer detector in EI mode. The carrier gas was helium and
injection was achieved on a 7683 series injector. GC-MS chiral phase analysis was
carried out with a supelco BetadexTM 120 fused silica capillary column (30 m ×
0.25 mm i.d., 0.25 μM film thickness). Conditions used for chiral phase GC-MS
analysis: 80 °C held for 20 min, then a gradient at 20 °C/min to 150 °C), 250 °C
injector temperature , 100:1 split ratio, 1.0 mL/min flow.
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5.1.5 Other analysis
IR experiments were recorded by the Nicolet Avatar 360 FT-IR by preparing the
sample in nujol method. Optical rotations determination was performed using a Perkin
Elmer Model 341 polarimeter, []D values are determined at 589 nm and given in 10-1
deg.cm2.g-1. Single X-ray diffraction analyses was carried out by Prof. A.M.Z. Slawin
on Robotic Diffractometer consisting of Mo sealed tube X-Ray system. The pKa
analysis was measured using a Hamilton pH electrode and the pH changes was
recorded by Fisher brand Hydrus 300 pH meter. The pH electrode was calibrated at
pH 4 and pH 7 standard buffer solution.
5.1.6 Glutamate receptor assay.
Assessment of 3F-NMDA activity at recombinant NMDARs.
Biological evaluation of the 3F-NMDA stereoisomers was performed at the Cellular
Neurophysiology and Pharmacology Centre for Integrative Physiology, at the
University of Edinburgh. The agonist activities of NMDA 2 and the 3F-NMDA
stereoisomers , D-3, D-4 and L-4, were assessed using two-electrode voltage-clamp
(TEVC) recordings from Xenopus laevis oocytes that had been inject with cRNA
coding for GluN1 and either GluN2A or GluN2B NMDAR subunits. 24 – 72 hours
following injection TEVC recordings were made at room temperature (18-21ºC) from
oocytes that were placed in a solution that contained (in mM): NaCl 115, KCl 2.5,
HEPES 10, BaCl2 1.8, EDTA 0.01; pH 7.3 with NaOH. Current and voltage
electrodes were made from thin-walled borosilicate glass and when filled with 0.3 M
KCl possessed resistances of between 1 and 2 M. Oocytes were voltage-clamped
at –40 mV. Application of solutions was controlled manually and data were filtered
at 10 Hz and digitized at 100 Hz. Two separate assessments of agonist potency were
made: (i) currents evoked by applying the same concentration of NMDA 2, D-3, D-4
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and L-4 to the same oocyte were measured in order to determine the relative
potencies of the 3F-NMDA stereoisomers compared to that of NMDA 2 itself. (ii)
for D-3 we determined the concentration required to produce a half-maximal response
(EC50) by constructing concentration-response curves using a range of concentrations
(3 – 300 M) so that its EC50 value could be compared to that of NMDA 2 at both
GluN2A - and GluN2B-containing NMDARs.
5.2 Protocols
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74.8 (CHOAc), 63.5 (OCH2), 62
(CH3). These data were in accorda130
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then the residue was concentrated
by distillation to give diethyl (2S
yellow oil (24.3 g, 97%).
[]D -28.4 (c 1.2, CHCl3), lit., 1 []
4.60 (1H, 2  d, J = 5.0 Hz, CHOH
m, OCH2) and 1.33 (t, J = 7.2 Hz,
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), 4.57 (1H, d, J = 5.0 Hz, CHBr), 4.30-4.19 (4H,
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ine (7.74 mL, 0.06 mol) was added dropwise to a
xysuccinate 87 (9.7 g, 0.05 mol) in EtOH (60 mL).
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-4.19 (4H, m, CH2), 3.88 (1H, dd, J =5.9, 21.6 Hz,
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OCH2), 58.7 (CH2), 37.9 (NCH3), 13.3 (CH3) and
CDCl3): -195.85 (1F, s, C(3)HF); IR (nujol mull)
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(-) Erythro diethyl (2S, 3S)-fluoro amino alcohol methylamine 90.
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2.3 (d, J = 22.7, CHN) and 31.8 (NCH3); δF
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-H]- C5H7NO4 F, 164.0365.
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10 % mol of Palladium on activ
3S)-benzylmethylamine 88 (3.0
the presence of hydrogen gas.
completion and filtered through
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of the reaction crude and purific
title compound 95 (2.1 g, 97%)
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ated carbon was added into a solution of diethyl (2S,
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ation over silica gel (hexane: EtOAc; 8:2) to give the
as a colourless oil.
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Cyclic sulfamate 96.
SOCl2 (0.59 mL, 8.1 mmol) and Et
a stirred solution of 95 (1.5 g, 6.85
was continue at -78 C for a further
RT and stirred for an additional 16
reduced pressure, and the crude pro
saturated NH4Cl solution (30 mL).
(3 ×50 mL) and the combined orga
under reduced pressure afforded the
The crude product was dissolved i
(1.1 g) and RuCl3.3H2O (5 mg)
warmed to RT and stirred for an ad
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reduced pressure, and the produc
combined organic layers were dr
pressure followed by purification o
compound 96 (750 mg, 75%) as a p
[]D +52.3 (c 1.0, CHCl3); δH (300
(1H, d, J = 7.0 Hz, CHN), 4.24-4.19
7.1 Hz, 2 х CH3); δc (300 MHz, CD
(CHN), 63.1 (CH2), 62.7 (CH2), 32
mull) υmax/cm-1 2721, 2663, 2365, 1138
3N (1.90 mL, 13.7 mmol) were added dropwise to
mmol) in dry DCM (40 mL) at –78 C. Stirring
2 h. The resulting solution was slowly warmed to
h. The reaction mixture was concentrated under
duct was partitioned between EtOAc (30 mL) and
The aqueous layer was then extracted into EtOAc
nic layers were dried with MgSO4. Concentration
crude product as yellow oil.
n CH3CN/water (1:1) and cooled to 0 C. NaIO4
were added. The resulting solution was slowly
ditional 4 h, at which point TLC analysis showed
n. The reaction mixture was concentrated under
t was extracted into EtOAc (30 mL) and the
ied with MgSO4. Concentration under reduced
ver silica gel (hexane: EtOAc ;7:3) gave the title
ale yellow oil.
MHz, CDCl3) 5.18 (1H, d, J = 7.0 Hz, CHO), 4.29
(4H, m, CH2), 2.89 (3H, s, CH3), 1.27 (3H, t, J =
Cl3) 165.0 (C=O), 164.3 (C=O), 74.5 (CHO), 63.4
.4 (NCH3), 13.9 (CH3) and 13.9 (CH3); IR (nujol
752, 1462, 1372, 1262, 1180, 1021 and 739; m/z
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C9H15NO7SNa, 304.0467.
meso Diethyl (2S,3R)- oxirane-2,3-dicarboxylate 99.[2,3]
n-Butyl lithium (2.5 M in hexane
tert-butyl hydroperoxide (5.5 M i
at –78 C. The mixture was stirre
solution of diethyl maleate 98 (9.
The reaction mixture was slowly
reaction was quenched with Na
vigorously for 1 h. The aqueous la
mL), and the combined organic
over MgSO4 and concentrated. T
EtOAc; 7:3) to give the title produ
δH (400 MHz, CDCl3) 4.15-4.10 (
1.20-1.16 (t, J = 7.2 Hz, 6H, 2
(OCH2), 52.4 (CH), 13.8 (2 × CH
were in accordance with the litera140
, 5.87 mL, 0.063 mol) was added to a solution of
n decane, 11.6 mL, 0.1 mol) in dried THF (30 mL)
d at the same temperature for 5 min, after which a
4 mL, 0.058 mol) in dry THF (10 mL) was added.
warmed to RT and stirring continued for 16 h. The
2S (4 mL) and the resulting mixture was stirred
yer was separated and extracted into EtOAc (3  50
layers were washed with saturated brine and dried
he residue was purified over silica gel (hexane:
ct 99 (5.4 g, 50%) as a colourless oil.
4H, q, J = 7.2 Hz, OCH2), 3.60 (s, 2H, 2  CH3) and
 CH3); δc (400 MHz, CDCl3) 165.6 (C=O), 61.7
3); m/z (ESI+) 211.01 [M+Na+] (100). These data
ture.2,3
(±) Threo diethyl 2-(benzyl(methyl)amino)-3-hydroxysuccinate
rac-100.
A solution of N-benzylmethylamin
suspension of rac-99 (9.7 g, 0.05 m
reflux for 15 h, and then the exces
under reduced pressure. The residue
to give the title compound rac-100 (
δH (400 MHz, CDCl3) 7.30-7.27 (5
4.32-4.17 (4H, m, OCH2), 3.92-3.72
CHN), 2.35 (3H, s, NCH3) and 1.34
CDCl3) 171.8 (C=O), 169.4 (C=O
128.4 (Ar CH), 128.4 (Ar CH), 127
60.8 (OCH2), 59.8 (CH2), 38.6
υmax/cm-1 3472, 1732, 1572, 1458
332.00 [M+Na+] (100), HRMS
C16H23NO5Na, 332.1474.141
e (7.74 mL, 0.06 mol) was added dropwise to a
ol) in EtOH (60 mL). The solution was stirred at
s of benzylmethylamine and EtOH were removed
was purified over silica gel (hexane:EtOAc; 6:4)
14.2 g, 92%) as colourless oil.
H, m, Ar-H), 4.55 (1H, d, J = 7.5 Hz, CHOH),
(2H, q, J = 7.1 Hz, CH2), 3.68 (1H, d, J = 7.5 Hz,
-1.30 (6H, t, J = 7.4 Hz, 2 ×CH3); δc (400 MHz,
), 138.4 (Ar C), 128.8 (Ar CH), 128,8 (Ar CH),
.3(Ar CH), 69.5 (COH), 66.8 (CHN), 61.5 (OCH2),
(NCH3) and 14.3 (2 х CH3); IR (nujol mull)
, 1372, 1258, 1151, 1098 and 1025; m/z (ESI+)
(ES+): Found 332.1474. Calcd. For [M+Na]+
(±) Threo Diethyl 2-(benzyl(methyl)amino)-3-fluorosuccinate rac-101.
Deoxo-fluorTM (8.34 mL, 0.03 m
mol) in dry DCM (20 mL) at RT.
excess of Deoxo-fluorTM was quen
reaction mixture was extracted in
layers were dried with MgSO4.
EtOAc; 9:1) to give the title comp
δH (400 MHz, CDCl3) 7.23-7.15 (
4.26-4.11 (4H, m, OCH2), 3.89 (1
13.5 Hz, CH2), 2.41 (3H, s) and 
168.9 (C=O), 167.9 (C=O), 139.1
CH), 128.2 (Ar CH), 127.1, (Ar-C
Hz, CHN), 61.7 (OCH2), 60.2 (O
δF {1H} (400MHz, CDCl3): -199
1677, 1574, 1455, 1375, 1271,
[M+Na+] (100). HRMS (ES+): Fo
334.1434.142
ol) was added to a solution of rac-100 (4 g, 0.01
The solution was stirred for 15 h at RT, and then the
ched with saturated NaHCO3 solution to pH 7. The
to EtOAc (3 х 50 mL) and the combined organic 
The residue was purified over silica gel (hexane:
ound rac-101 (2.71 g, 87%) as a pale yellow oil.
5H, m, Ar H), 5.39 (1H, dd, J = 4.0, 47.9 Hz, CHF),
H, dd, J = 4.0, 31.7 Hz, CHN), 3.87-3.76 (2H, q, J =
1.27-1.24 (6H, m, 2 х CH3); δc (400 MHz, CDCl3)
(Ar C), 128.6 (Ar CH), 128.6 (Ar CH), 128.2 (Ar
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und 334.1431. Calcd. For [M+Na]+ C16H22NO4 FNa,
(±) Threo diethyl 2-fluoro-3-(methylamino)succinate rac-102.
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(3.2 g, 0.01 mol) in EtOH (20 m
The reaction mixture was follow
and filtered through celite. The
mL) and dried with MgSO4. C
compound rac-102 (1.6 g, 87%)
δH (300 MHz, CDCl3) 5.17 (1H
3.61 (1H, dd, J = 2.4, 31.4 Hz,
CH3); δc (300 MHZ, CDCl3) 17
64.3 (d, J = 20.2 Hz, CNR), 61.
δF {1H} (400MHz, CDCl3): -20
1693, 1577, 1455, 1373, 1260,
[M+H+] (100). HRMS (ES+): F
244.1000.143
carbon (30 mg) was added into a solution of rac-101
L) and stirred at RT in the presence of hydrogen gas.
ed by TLC until the reaction had gone to completion
 reaction mixture was extracted into EtOAc (3 х 50 
oncentration of the reaction crude to give the title
as a colourless oil.
,dd, J = 2.4, 47.7 Hz, CHF), 4.30-4.15 (4H, m, OCH2),
CHN), 2.36 (3H, s, NCH3) and 1.27-1.22 (6H, m, 2 х 
0.2 (C=O), 167.4 (C=O), 90.8 (d, J = 189.7 Hz, CHF),
8 (OCH2), 61.7 (OCH2), 35.6 (NCH3) and 14.0 (CH3);
4.3 (1F, s, C(3)HF); IR (nujol mull) υmax/cm-1 1741,
1131, 1074, 1035, 795 and 738; m/z (ESI+) 222.0
ound 244.0961. Calcd. For [M+Na]+ C9H16NO4 FNa,
(±) Threo (2S,3R)-3F NMDA HCl rac-73.
A few drops of EtOH was added
complete dissolution, followed by
heated under refluxed for 48 h an
and concentrated under reduced p
30%) as a pale yellow oil.
δH (300 MHz, CDCl3) 5.47-5.32
27.4 Hz, CHN) and 2.69 (3H, N
(C=O), 87.9 (d, J = 189.5 Hz), 62
(300 MHz, CDCl3): -196.38 (1F,
(ES-): Found 164.0359. Calcd. Fo144
into a solution of rac-102 (1.6 g, 7.23 mmol) until
adding HCl (4M, 4 mL). The reaction mixture was
d the reaction was then diluted with DCM (30 mL)
ressure to give the title compound rac-73 (480 mg,
(1H, dd, J = 45.1 Hz, CHF), 4.31-4.22 (1H, dd, J =
CH3); δc (300 MHz, CDCl3) 171.0 (C=O), 168.6
.5 (d, J = 21.7 Hz, CHN) and 32.3 (NCH3); δF {1H}
s, C(3)HF). m/z (ESI-) 164 [M-H+] (100). HRMS
r [M-H]- C5H7NO4F, 164.0369.
meso Dibenzyl (2S,3R)-oxirane-2,3-dicarboxylate 104.[4]
Oxalyl chloride (13.5 mL, 0.16
acid 103 (10.0 g, 0.07 mol) in d
temperature for 1 h and then slo
h. The crude product was obta
purification for the subsequent
crude product in dry THF (40 m
added into the reaction mixture
min. The resulting mixture was
aqueous layer was separated an
combined organic layers were
Concentration under reduced
EtOAc; 8:2) afforded the title pr
δH (300 MHz, CDCl3) 7.40-7.3
CH); δc (CDCl3) 134.5 (Ar C),
(Ar CH), 67.6 (CH) and 52.6
(ES+): Found 335.0896 Calcd. F
in accordance with the literature145
mol) was added to a solution of cis-epoxy succinic
ry THF at 0 C. The mixture was stirred at the same
wly warmed to RT and heated at reflux for another 2
ined after solvent evaporation and was used without
reaction. Catalytic amount of DMF was added to the
L) at 0 C. Benzyl bromide (18.0 mL, 0.15 mol) was
and followed by dropwise of pyridine (5 mL) over 20
slowly warmed to RT and left to stir for 16 h. The
d extracted into ethyl acetate (3  50 mL), and the
washed with saturated brine and dried over MgSO4.
pressure and purification over silica gel (hexane:
oduct 104 as a colourless oil (20.1 g, 86%).
4 (10H, m, Ar H), 5.13 (2H, s, OCH2), 3.77 (s, 2H,
128.7 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.6
(OCH2); m/z (ESI+) 334.9 [M+Na+] (100). HRMS
or [M+Na]+ C18H16O5 Na, 335.0890. These data were
.4
(±) Threo dibenzyl 2-(benzyl(methyl)amino)-3-hydroxysuccinate
rac-105.
A solution of N-benzylmethyla
dropwise to a suspension of 104
was stirred at reflux for 15 h, an
were removed under reduced
(hexane:EtOAc; 6:4) to give th
yellow oil.
δH (300 MHz, CDCl3) 7.42-7.26
d, J = 7.6 Hz, CHOH), 3.98-3.7
(3H, s, NCH3); δc (300 MHz, CD
(Ar C), 128.8 (Ar CH), 128.8 (A
128.5 (Ar CH), 128.4 (Ar CH),
OCH2), 59.6 (CH2), 38.7 (NCH3
1372, 1258, 1151, 1098 and 10
Found 456.1787. Calcd. For [M+146
mine in ethanol (4.64 mL, 0.036 mol) was added
(10.0 g, 0.03 mol) in ethanol (60 mL). The solution
d then the excess of N-benzylmethylamine and EtOH
pressure. The residue was purified over silica gel
e title compound rac-105 (12.5 g, 92%) as a pale
(15H, m, Ar H), 5.31-5.14 (4H, m, OCH2), 4.72 (1H,
5 (1H, q, CH2), 3.84 (2H, d, J = 7.6 Hz, CHN), 2.38
Cl3) 171.7 (C=O), 169.3 (C=O), 138.3 (Ar C), 135.5
r CH), 128.6 (Ar CH), 128.6 (Ar CH), 128.5 (Ar CH),
127.4 (Ar CH), 69.6 (COH), 67.3 (CHN), 66.5 (2 
); IR (nujol mull) υmax/cm-1; 3472, 1732, 1572, 1458,
25; m/z (ESI+) 456.0 [M+Na+] (100), HRMS (ES+):
Na]+ C26H27NO5Na, 456.1781.
(±) Threo dibenzyl 2-(benzyl(methyl)amino)-3-fluorosuccinate
rac-106.
DeoxofluorTM (5.65 mL, 26.3 m
mmol) in dry DCM (20 mL) at
the excess of DeoxofluorTM wa
The reaction mixture was extra
The residue was purified over
compound rac-106 (3.37 g, 84%
δH (300 MHz, CDCl3) 7.42-7.2
CHF), 5.36-5.19 (4H, m, OCH2
= 13.5 Hz, CH2), 2.51 (3H, s,
(C=O), 139.3 (Ar C), 135.7 (Ar
128.9 (Ar CH), 128.7 (Ar CH),
CHF), 67.8 (OCH2), 67.3 (OC
(NCH3); δF {1H} (400MHz,
υmax/cm-1 1744, 1691, 1576, 14
(ESI+) 458.00 [M+Na+], (60). H
C26H26NO4FNa, 458.1738.147
mol) was added into a solution of rac-105 (4 g, 8.77
RT. The solution was stirred for 15 h at RT, and then
s quenched with saturated NaHCO3 solution to pH 7.
cted into EtOAc (3 х 50 mL) and dried with MgSO4.
silica gel (hexane: EtOAc; 9:1) to afford the title
) as a pale yellow oil.
5 (15, m, Ar-H), 5.59 (1H, dd, J = 3.77, 47.9 Hz,
), 4.06 (1H, dd, J = 3.8, 31.9 Hz), 4.00-3.83 (2H, q, J
NCH3); δc (300 MHz, CDCl3) 168.0 (C=O), 167.7
CH), 135.2 (Ar CH), 129.1 (Ar CH), 129.0 (Ar CH),
128.6 (Ar CH), 127.5 (Ar CH), 92.0 (d, J = 192.2 Hz,
H2), 66.8 (d, J = 36.6 Hz, CHN), 60.5 (CH2), 38.8
CDCl3): -198.6 (1F, s, C(3)HF); IR (nujol mull)
58, 1376, 1270, 1141, 1094, 1037, 796 and 739; m/z
RMS (ES+): Found 458.1744. Calcd. For [M+Na]+
(±) Threo (2S,3R)-3F NMDA HCl rac-73.
10 % Palladium on activated carbon
mmol) in ethyl acetate (20 mL) and
reaction mixture was followed by
then filtered through celite. The re
mL). Concentration under reduced p
mL) to give the title compound rac-
δH (300 MHz, CDCl3) 5.40 (1H, dd
CHN) and 2.69 (3H, s, NCH3); δc
87.9 (d, J = 189.5 Hz, CHF), 62.5 (
(300MHz, CDCl3): -196.38 (1F, dd
(ES-): Found 164.0359. Calcd. For [148
was added into a solution of rac-106 (1.6 g, 3.67
stirred at RT in the presence of hydrogen gas. The
TLC until the reaction had gone completion and
action mixture was extracted into EtOAc (3 х 50 
ressure and followed by addition of HCl (1M, 0.1
73 as pale yellow oil (517 mg, 86%).
, J = 45.1 Hz, CHF), 4.27 (1H, dd, J = 27.4 Hz,
(300 MHz, CDCl3) 171.0 (C=O), 168.6 (C=O),
d, J = 21.7 Hz, CHN), and 32.3 (NCH3); δF {1H}
, C(3)HF). m/z (ESI-) 164 [M-H+] (100). HRMS
M-H]- C5H7NO4F, 164.0369.
Mixture of diastereoisomers dibenzyl –hydroxy -3-(methyl
(S)-1-phenylethyl)amino) succinate (S)-107 and (S)-108.
A solution of (S)-(
suspension of 104
stirred at reflux for
solution (3  50 m
mL). Solvent evapo
the mixture of dias
oil.
Data for the mixtu
7.41-7.21 (30H, m)
(1H, d, J = 8.6 Hz,
CH), 3.91 (2H,q, J
2.21 (3H, s, NCH3
128.7 (Ar CH), 128
(Ar CH), 127.3 (A
67.0 (CHN), 66.7
(NCH3), 33.7 (NCH
1731, 1572, 1448,
HRMS (ES+): Foun149
-)-N, α-dimethylbenzylamine (19.70 mL) was added dropwise to a 
(10.0 g, 0.07 mol) in DMF (10 mL) and the resulting solution was
4 h. The reaction mixture was worked up with saturated NaHCO3
L) and the aqueous layer was washed with ethyl acetate (3  50
ration and purification over silica gel (hexane:EtOAc; 8:2) to give
tereoisomers (S)-107 and (S)-108 (26.5 g, 85%) as a pale yellow
re of diastereoisomers (S)-107 and (S)-108: δH (300MHz, CDCl3)
, 5.33-5.00 (8H, m, OCH2), 4.63 (1H, d, J = 8.3 Hz, CHOH), 4.52
CHOH), 4.16 (1H, d, J = 8.4 Hz, CHN), 3.98 (2H, q, J = 6.7 Hz ,
= 6.4 Hz , CH), 3.69 (1H, d, J = 8.5 Hz, CHN), 2.43 (3H, s, NCH3),
); δc (300 MHz, CDCl3) 171.3 (C=O), 169.4 (C=O), 143.1 (Ar C),
.6 (Ar CH), 128.5 (Ar CH), 128.3 (Ar CH), 128.2 (Ar CH), 127.6
r CH), 127.1 (Ar CH), 68.8 (CHOH),68.5 (CHOH), 67.3 (CHN),
(2  OCH2), 66.6 (2  OCH2), 63.0 (NCH), 62.6 (NCH), 35.7
3), 21.1 (CH3) and 20.5 (CH3Ph); IR (nujol mull) υmax/cm-1 3470,
1362, 1253, 1150, 1097 and 1020; m/z (ESI+) 470.1 [M+Na+] (100),
d 470.1943. Calcd. For [M+Na]+ C27H29NO5Na, 470.1938.
Mixture of diastereoisomers dibenzyl 2-hydroxy -3-
(methyl((R)-1-phenylethyl)amino) succinate (R)-108 and (R)-107.
Mixture of diaster
(S)-107 and (S)-10
as a pale yellow oil
Data for the mixtu
7.41-7.21 (30H, m)
(1H, d, J = 8.6 Hz,
CH), 3.91 (2H,q, J
2.21 (3H, s, NCH3
CH), 128.6 (Ar CH
127.1 (Ar CH), 68
OCH2), 66.6 (2  O
(CH3) and 20.5 (CH
1150, 1097 and 1
470.1943. Calcd. F150
eoisomer (R)-108 and (R)-107 was synthesized as described for
8. Compound (R)-108 and (R)-107 (27.8 g, 89%) was synthesized
.
re of diastereoisomers (R)-108 and (R)-107: δH (300 MHz, CDCl3)
, 5.33-5.00 (8H, m, OCH2), 4.63 (1H, d, J = 8.3 Hz, CHOH), 4.52
CHOH), 4.16 (1H, d, J = 8.4 Hz, CHN), 3.98 (2H, q, J = 6.6 Hz ,
= 6.4 Hz, CH), 3.69 (1H, d, J = 8.5 Hz, CHN), 2.43 (3H, s, NCH3),
); δc (CDCl3) 171.3 (C=O), 169.4 (C=O), 143.1 (Ar C), 128.7 (Ar
), 128.5 (Ar CH), 128.3 (Ar CH), 127.6 (Ar CH), 127.3 (Ar CH),
.8 (CHOH),68.5 (CHOH), 67.3 (CHN), 67.0 (CHN), 66.7 (2 
CH2), 63.0 (NCH), 62.6 (NCH), 35.7 (NCH3), 33.7 (NCH3), 21.1
3); IR (nujol mull) υmax/cm-13470, 1731, 1572, 1448, 1362, 1253,
020; m/z (ESI+) 470.1 [M+Na+], 100%), HRMS (ES+): Found
or [M+Na]+ C27H29NO5Na, 470.1938.
(-) Dibenzyl 2-fluoro-3- (methyl ((S)- 1-phenylethyl)amino) succinate
(S)-109 or (S)-110.
DeoxofluorTM (5.76 m
g, 8.94 mmol) in dry
and then the excess
to pH 7. The react
combined organic lay
gel (hexane: EtOAc;
(3.37 g, 43%) as a pa
Data for either (S)-1
7.38-7.05 (15, m, A
OCH2), 3.90 (1H, dd
s, NCH3) and 1.58 (3
128.4 (Ar CH), 128.3
J = 49.9 Hz, CHN),
-195.7 (1F, s, C(3)HF
1096, 1073, 800 an
472.1900. Calcd. For151
l, 26.8 mmol) was added to a solution of (S)-107 and (S)-108 (4
DCM (20 mL) at RT. The solution was stirred for 15 h at RT,
of DeoxofluorTM was quenched with saturated NaHCO3 solution
ion mixture was extracted into EtOAc (3 х 50 mL) and the 
ers were dried with MgSO4. The residue was purified over silica
9:1) to give either one of the stereoisomer of (S)-109 or (S)-110
le yellow oil.
09 or (S)-110: []D – 69.5 (c 0.6, D2O); δH (400 MHz, CDCl3)
r-H), 5.40 (1H, dd, J = 4.6 Hz, 48.4 Hz, CHF), 5.27 (4H, m,
, J = 4.3, 32.4 Hz, CHN), 3.95 (1H, q, J = 6.3 Hz, CH), 2.66 (3H,
H, s, CH3); δc (400 MHz, CDCl3) 129.6 (Ar CH), 128.6 (Ar CH),
(Ar CH), 127.5 (Ar CH), 91.5 (d, J = 231.8 Hz, CHF), 67.2 (d,
63.1 (CH), 35.2 (NCH3), 21.3 (CH3); δF {1H} (400MHz, CDCl3):
); IR (nujol mull) υmax/cm-1 2986, 1609, 1451, 1327, 1276, 1163,
d 751; m/z (ESI+) 472.1 [M+Na+] (30). HRMS (ES+): Found
[M+Na]+ C27H28NO4 FNa, 458.1895.
(+) Dibenzyl 2- fluoro-3- (methyl((R)-1- phenylethyl)amino) succinate
(R)-110 or (R)-109.
The stereoisomer
(R)-110 or (R)-109
Data for either (R)
7.38-7.05 (15, m, A
3.90 (1H, dd, J =
NCH3) and 1.58 (3
128.4 (Ar CH), 128
J = 49.9 Hz, CHN
CDCl3): -195.7 (1F
1276, 1163, 1096,
Found 472.1900. C152
of dibenzyl 2-fluoro-3-(methyl((R)-1-phenylethyl)amino)succinate
was synthesized as described for (S)-109 or (S)-110.
-110 or (R)-109: []D + 52.2 (c 0.6, D2O); δH (300 MHz, CDCl3)
r H), 5.40 (1H, dd, J = 4.6, 48.4 Hz, CHF), 5.27 (4H, m, OCH2),
4.3, 32.4 Hz, CHN), 3.95 (1H, q, J = 6.8 Hz, CH), 2.66 (3H, s,
H, s, CH3); δc (300 MHz, CDCl3) 129.0 (Ar C), 128.6 (Ar CH),
.3 (Ar CH), 127.5 (Ar CH), 91.5 (d, J = 231.8 Hz, CHF), 67.2 (d,
), 63.1 (CH), 35.2 (NCH3), 21.3 (CH3Ph); δF {1H} (400MHz,
, s, C(3)HF); IR (nujol mull) υmax/cm-1 2986, 1609, 1451, 1327,
1073, 800 and 751; m/z (ESI+) 472.1 [M+Na+] (30). HRMS (ES+):
alcd. For [M+Na]+ C27H28NO4 FNa, 458.1895.
Threo (2R, 3S)- or (2S, 3R)- 3-fluoro NMDA HCl (-)-73.
10 % Palladium on
(S)-110 (1.6 g, 3.67
of hydrogen gas. Th
gone to completion
extracted into EtOAc
0.1 mL) was added t
3-fluoro NMDA HCl
[]D -2.1 (c 1.0, D2O
(1H, dd, J = 27.4 H
(C=O), 87.9 (d, J = 1
{1H} (400MHz, CD
HRMS (ES-): Found153
activated carbon (30 mg) was added to a solution of (S)-109 or
mmol) in ethyl acetate (20 mL) and stirred at RT in the presence
e reaction mixture was followed by TLC until the reaction had
and filtered through celite. The reaction mixture was then
 (3 х 50 mL). Concentration of the reaction crude and HCl (1M, 
o give either one of the stereoisomer (-) (2R,3S)- or (-) (2S,3R)-
73 (517 mg, 85 %) as a pale yellow oil.
); δH (500 MHz, CDCl3) 5.39 (1H, dd, J = 45.1 Hz, CHF), 4.26
z, CHN) and 2.69 (3H, NCH3); δc (CDCl3) 171.0 (C=O), 168.6
89.5 Hz, CHF), 62.5 (d, J = 21.7 Hz, CHN), and 32.3 (NCH3); δF
Cl3): -196.38 (1F, s, C(3)HF). m/z (ESI-) 164 [M-H+] (100).
164.0359. Calcd. For [M-H]- C5H7NO4F, 164.0369.
Threo (2S,3R)- or (2R,3S)- 3-fluoro NMDA HCl (+)-73.
10 % Palladium on ac
(R)-109 (1.6 g, 3.67 m
of hydrogen gas. The
gone completion and
extracted into EtOAc (
0.1 mL) was added
(2R,3S)-3-fluoro NMD
[]D + 2.9 (c 1.0, D2O)
(1H, dd, J = 27.4 Hz, C
168.6 (C=O), 87.9 (d,
(NCH3); δF {1H} (400
(100). HRMS (ES-): Fo154
tivated carbon (30 mg) was added to a solution of (R)-110 or
mol) in ethyl acetate (20 mL) and stirred at RT in the presence
reaction mixture was followed by TLC until the reaction had
then filtered through celite. The reaction mixture was then
3 х 50 mL). Concentration of the crude reaction and HCl (1M, 
to give either one of the stereoisomer (+) (2S,3R)- or (+)
A HCl (+)-73 (517 mg, 85%) as a pale yellow oil.
; δH (300 MHz, CDCl3) 5.39 (1H, dd, J = 45.1 Hz, CHF), 4.26
HN) and 2.69 (3H, NCH3); δc (300 MHz, CDCl3) 171.0 (C=O),
J = 189.5 Hz, CHF), 62.5 (d, J = 21.7 Hz, CHN), and 32.3
MHz, CDCl3): -196.38 (1F, s, C(3)HF). m/z (ESI-) 164 [M-H+]
und 164.0359. Calcd. For [M-H]- C5H7NO4F, 164.0369
Triethyl oxalocitrolactone ester 91[5]
HCl in diethyl ether (1M, 0.1 mL
ether (20 ml) and stirred at RT in
crude gave the title compound 91
δH (400 MHz, CDCl3) 4.32-4.00
CH2) and 1.36-1.23 (9H, m, 3 × C
58.4 (CH2), 52.8 (CH), 31.9 (CH2
These data were in accordance wi155
) was added to a solution of 89 (0.2 g, 0.6 mmol) in
the presence of argon. Concentration of the reaction
(0.1 g, 51%) as a colourless oil.
(6H, m, 3 × CH2), 3.68 (1H, s, CH), 2.46 (2H, s,
H3); δc (400 MHz, CDCl3) 62.3 (CH2), 61.2 (CH2),
) and 14.0 (3 × CH3). m/z (ESI-) 329 [M-H+] (100).
th the literature.5
3-(3-(Trifluoromethyl)phenyl)propanoic acid 144.[6]
10 % Palladium on activated
0.04 mol) in EtOH (20 ml) a
reaction was monitored by T
filtered through celite. The re
Concentration of the reaction
colourless oil.
δH (400 MHz, CDCl3) 11.9 (1
7.4 Hz, CH2) and 2.74 (2H, t,
141.0 (Ar C), 131.7 (Ar CH)
(CH2) and 30.2 (CH2); δF {1
mull) υmax/cm-1 3354, 2998, 1
(ESI-) 217 [M-H+] (100). Thes156
carbon (40 mg) was added to a solution of 140 (10.0 g,
nd stirred at RT in the presence of hydrogen gas. The
LC until the reaction had gone completion and then
action mixture was extracted into EtOAc (3 х 50 mL). 
crude gave the title compound 144 (8.5 g, 98%) as a
H, s, COOH), 7.52-7.43 (4H, m, Ar-H), 3.04 (2H, t, J =
J = 7.6 Hz, CH2); δc (400 MHz, CDCl3) 179.60 (C=O),
, 129.0 (Ar CH), 125.0 (Ar CH), 123.3 (Ar CH), 35.5
H} (400MHz, CDCl3): -63.11 (3F, s, CF3); IR (nujol
708, 1484, 1414, 1275, 1110, 888, 827 and 764. m/z
e data were in accordance with the literature.6
3-(3-(trifluoromethyl)phenyl)propan-1-ol 145.[6]
Lithium aluminium hydride (11
0.02 mol) in dry THF (30 mL).
reaction mixture was quenched
with EtOAc (3 х 50 mL). Conc
gel to give the title compound 14
δH (400 MHz, CDCl3) 7.49-7.3
2.78 (2H, t, J = 7.7 Hz, CH2) an
C), 131.8 (Ar CH), 128.7 (Ar C
(CH2) and 30.2 (CH2); δF {1H
mull) υmax/cm-1 3353, 2997, 148
204 M+. (40). These data were in157
.3 g, 0.03 mol) was added to a solution of 144 (5.0 g,
The reaction mixture was heated at reflux for 1 h. The
with saturated KOH solution (15 mL) and washed
entration of the organic layers and purified over silica 
5 (3.87 g, 95%) as a colourless oil.
8 (4H, m, Ar-H), 3.67 (2H, t, J = 6.6 Hz, CH2OH),
d 1.91 (2H, m, CH2); δc (400 MHz, CDCl3) 142.8 (Ar
H), 125.0 (Ar CH), 122.7 (Ar CH), 61.6 (COH), 33.9
} (400MHz, CDCl3): -63.06 (3F, s, CF3); IR (nujol
4, 1318, 1273, 1100, 908, 824 and 754. m/z (GC-MS)
accordance with the literature.6
3-(3-(trifluoromethyl)phenyl)propanal 146.[6]
DMP (12.7 g, 0.03 mol) was
(20 mL) at 0 °C and was slow
with saturated NaHCO3 soluti
(3 х 50 mL) and the combi
pressure. Purification over
compound 146 (2.4 g, 60%) as
δH (400 MHz, CDCl3): 9.74 (
Hz, CH2) and 2.74 (2H, t, J =
127.88 (Ar CH), 125.5 (Ar CH
(400MHz, CDCl3): -63.13 (3F
1485, 1330, 1275, 1165, 913,
in accordance with the literatu158
added into a solution of 145 (5.0 g, 0.02 mol) in DCM
ly warmed to RT. After 1 h, the reaction was quenched
on (30 ml). The aqueous layer was washed with EtOAc
ned organic layers were concentrated under reduced 
silica gel (hexane: EtOAc; 9:1) afforded the title
a colourless oil.
1H, s, CHO), 7.39 (4H, m, Ar-H), 2.93 (2H, t, J = 7.6
7.6 Hz, CH2); δc (CDCl3) 143.2 (Ar C), 128.6 (Ar CH),
), 125.5 (Ar CH), 37.4 (CH2) and 31.1 (CH2); δF {1H}
, s, CF3); IR (nujol mull) υmax/cm-1 3006, 2988, 1613,
801 and 750. m/z (ESI+) 202 [M+] (40). These data were
re.6
(R)-2-fluoro-3-(3-(trifluoromethyl)phenyl)propanal (R)-148.
N-Fluorobenzenesulfonimide
-(+)-2,2,3-trimethyl-5-benzyl-
15 % mol) was added to a solu
at –15 °C. The reaction was m
material was consumed. After
was added into the reaction an
quenched with NaHCO3 solut
with (NH4)2SO4 and partitione
was concentrated under reduce
7:3) to give the title compound
[]D + 9.55 (c 2.0, CHCl3); δH
48.5 Hz, CHF), 3.67 (2H, m
132.7 (Ar CH), 129.0 (Ar CH)
CHF), 64.1 (d, J = 22.2 Hz, C
CDCl3): -63.1 (3F, s, CF3), -
(nujol mull) υmax/cm-1 3353,
(CI+) 203.07 [M-F-] (100).
C10H10OF3, 203.0668.159
(7.80 g, 0.02 mol) and (5R)
4-imidazolidinone dichloroacetic acid salt (516 mg,
tion of 146 (2.0 g, 9.9 mmol) in THF/Isopropanol (9:1)
onitored by chiral phase GC-MS until all the starting
16 h, lithium aluminium hydride (564 mg, 0.01 mol)
d continued stirring for 1 h. The reaction mixture was
ion (30 ml) at –15 °C. The aqueous layer was washed
d with EtOAc (3 х 50 mL). The combined organic layer 
d pressure and purified over silica gel (hexane: EtOAc;
(R)-148 (2.4 g, 80%) as a pale yellow oil.
(300 MHz, CDCl3): 7.43 (5H, m, Ar-H), 4.71 (dm, J =
, CH2) and 2.97 (2H, m, CH2); δc (300 MHz, CDCl3)
, 125.9 (Ar CH), 123.7 (Ar CH), 94.8 (d, J = 172.8 Hz,
OH) and 37.2 (d, J = 21.6 Hz, CH2); δF {1H} (400MHz,
189.0 (1F, s, CHF). m/z (ESI-) 203 (M-F-, 40%); IR
2934, 1461, 1328, 1199, 1072, 908, 835 and 752. m/z
HRMS (CI+): Found 203.0684. Calcd. For (M-F)-
(S)-2-Fluoro-3-(3-(trifluoromethyl)phenyl)propan-1-ol (S)-148.
Compound (S)-148 was prepa
146. The product was obtaine
identical to (R)-148; []D –14.
(CI+): Found 203.0684. Calcd.160
red following the procedure for (R)-148, starting with
d as a pale yellow oil (2.4 g, 80 %). Spectra data were
4 (c 2.1, CHCl3); m/z (CI+) 203.07 [M-F-] (100). HRMS
For [M-F]- C10H10OF3, 203.0668.
(2R,1’R)-2-Fluoro Cinacalcet HCl 123.
Trifluoromethanesulfoni
Et3N (0.33 mL, 4.5 mmo
0 °C. (R)-(148) (500 m
cannula and was left to
warmed to RT and con
saturated NaHCO3 soluti
х 50 mL). The combined
afford the crude mixture
reaction without purifica
(R)-1-(1-napthyl)ethylam
(200.0 mg, 0.6 mmol) in
h. After 16 h, the rea
Purification over silica
(2R,1’R)-123 (199.5 mg,
was added into (2R,1’R)-
[]D + 4.4 (c 1.0, CHCl3
J = 47.9 Hz, CHF), 4.92
and 1.64 (3H, d, J = 5.8
131.0 (Ar C), 129.1 (Ar
(Ar CH), 125.8 (Ar CH)
54.1 (CH), 49.8 (d, J = 2161
c anhydride (0.71 mL, 3.4 mmol) was added to a solution of
l) and DMAP (27.9 mg, 0.2 mmol) in dry DCM (30 mL) at
g, 2.2 mmol) was added into the reaction mixture through
stir for 2 h at 0 °C. The reaction mixture was subsequently
tinued stirring for 16 h. The reaction was quenched with
on (30 ml) and the aqueous layer was washed with EtOAc (3
 organic layers were concentrated under reduced pressure to 
of (R)-149. The crude mixture (R)-149 was used for the next
tion.
ine (0.11 ml, 0.7 mmol) was added into a solution of (R)-149
toluene (15 mL) and the reaction was heated at reflux for 16
ction mixture was concentrated under reduced pressure.
gel (hexane: EtOAc; 8:2) to afford the title compound
95%) as a pale yellow oil. HCl in diethyl ether (0.1 mL, 1M)
123 to afford the hydrochloride salt.
); δH (400 MHz, CDCl3): 8.02-7.22 (11H, m, Ar-H), 5.07 (dm,
-4.85 (1H, q, J = 6.4 Hz, CHMe), 2.85-2.72 (4H, m, 2×CH2)
Hz, CH3); δc (400 MHz, CDCl3) 133.9 (Ar C), 132.6 (Ar CH),
CH), 128.9 (Ar CH), 128.5 (Ar CH), 126.5 (Ar CH), 126.0
, 123.8 (Ar CH), 122.3 (Ar CH), 92.9 (d, J = 172.8 Hz, CF),
2.2 Hz, CH2), 39.0 (d, J = 20.9 Hz, CH2) and 22.5 (CH3); δF
162
{1H} (400 MHz, CDCl3): -63.0 (3F, s, CF3), -184.2 (1F, s, CF); IR (nujol mull)
υmax/cm-1 2985, 1453, 1329, 1207, 1074, 1026, 801 and 750. m/z (ESI+) 398 [M+Na+]
(30). HRMS (ES+): Found 376.1676. Calcd. For [M+H]+ C10H10OF3, 376.1683.
(2S,1’R)-2-fluoro Cinacalcet HCl 124.
Trifluoromethanesulfonic
Et3N (0.33 mL, 4.5 mmol
0 °C. (S)-148 (258 mg, 1
cannula and was left to st
warmed to RT and stirri
saturated NaHCO3 solution
х 50 mL). The combined o
afford (S)-149 as a crude m
The crude mixture (S)-1
(R)-1-(1-napthyl)ethylamin
(245 mg, 0.7 mmol) in tolu
After 16 h, the reaction mi
over silica gel (hexane: EtO
78%) as a pale yellow o
(2S,1’R)-124 to afford the
[]D – 8.0 (c 0.6, CHCl3)
Hz, CHF), 5.20-5.14 (1H,
(3H, d, J = 6.7 Hz, CH3);
131.6 (Ar CH), 129.4 (Ar
(Ar CH), 125.9 (Ar CH),
CH), 94.6 (d, J = 171.6 Hz163
anhydride (0.3 mL, 1.8 mmol) was added to a solution of
) and DMAP (15 mg, 0.1 mmol) in dry DCM (30 mL) at
.2 mmol) was added into the reaction mixture through a
ir for 2 h at 0 °C. The reaction mixture was subsequently
ng continued for 16 h. The reaction was quenched with
(30 ml) and the aqueous layer was washed with EtOAc (3
rganic layers were concentrated under reduced pressure to 
ixture.
49 was used for the next reaction without purification.
e (0.2 ml, 1.8 mmol) was added into a solution of (S)-149
ene (15 mL) and the reaction was heated at reflux for 16 h.
xture was concentrated under reduced pressure. Purification
Ac; 8:2) to give the title compound (2S,1’R)-124 (207 mg,
il. HCl in diethyl ether (0.1 mL, 1 M) was added into
hydrochloride salt.
; δH (CDCl3): 8.22-7.39 (11H, m, Ar-H), 5.39 (dm, J = 49.2
q, J = 6.7 Hz, CHMe), 3.17-2.79 (4H, m, 2×CH2) and 1.61
δc (CDCl3) 138.2 (Ar C), 134.4 (Ar CH), 133.1 (Ar CH),
CH), 129.2 (Ar CH), 128.0 (Ar CH), 126.4 (Ar CH), 126.1
123.9 (Ar CH), 123.9 (Ar CH), 123.4 (Ar CH), 123.1 (Ar
, CHF), 54.1 (CH), 51.1 (d, J = 21.5 Hz, CH2) and 39.5 (d,
164
J = 21.6 Hz, CH2) and 23.9 (CH3); δF (400 MHz, CDCl3): -63.1 (3F, s, CF3), -183.6
(1F, s, CF). m/z (ESI+) 398 [M+Na+] (30). HRMS (ES+): Found 376.1688. Calcd. For
[M+H]+ C10H10OF3, 376.1683.
3-(3-(Pentafluorosulfur)phenyl)benzyl bromide 154.
Phosphorus tribromide (4.5 mL,
0.04 mol) in EtOH (20 mL) at RT
at 0 °C. The aqueous layer was w
layer was combined. Concentratio
gel (hexane: EtOAc; 9:1) to affo
yellow oil.
δH (300 MHz, CDCl3) 7.81-7.45 (
CDCl3) 132.1 (Ar CH), 129.2 (A
(CH2); δF (400MHz, CDCl3): 62.
IR (nujol mull) υmax/cm-1 3027, 2
m/z (CI) 278 [M-F-] (55). HR
C7H6SF4Br, 276.9310.165
0.05 mol) was added to a solution of 153 (10.0 g,
. After 3 h, the reaction was work-up with NaHCO3
ashed with ethyl acetate (3 ×50 mL) and the organic
n under reduce pressure and purification over silica
rd the title compound 154 (9.0 g,76%) as a pale
4H, m, Ar-H) and 4.52 (2H, s, CH2); δc (300 MHz,
r CH), 126.5 (Ar CH), 125.9 (Ar CH) and 31.6
2 (1F, d, J = 150.1 Hz, Feq) and 83.3 (4F, q, Faxial);
984, 1493, 1319, 1158, 1027, 913, 827 and 7549.
MS (CI+): Found 276.9302. Calcd. For [M-F]+
3-(3-(Pentafluorosulfur)phenyl)propanoic acid 155.
Diethyl malonic (2.5 mL, 0.0
added to a solution of 154 (5.0
h of stirring, the reaction m
continued for 16 h. After all
TLC analysis, the reaction w
ice-cooled water bath. The aqu
and the combined organic laye
product was used for the next
NaOH (6 M, 30 mL) and EtOH
then heated at reflux. After 16
solution to pH 2 at 0 °C and
×50 mL). The organic layers w
under reduced pressure. The c
purification.
Concentrated HCl (4M, 30
aforementioned reaction and t
reaction mixture was quenche
with concentrated HCl solutio
ethyl acetate (3 × 100 mL).
reduced pressure and purifica
the title compound 155 (2.3 g,166
1 mol) and sodium hydride (404.0 mg, 0.01 mol) was
g, 0.01 mol) in a dry THF ( 50 mL) at –78 °C. After 1
ixture was subsequently warmed to RT and stirring
the starting material was consumed, as confirmed by
as quenched with hydrochloric acid (10 mL) in an
eous layer was washed with ethyl acetate (3 ×50 mL)
rs were concentrated under reduced pressure. The crude
reaction without purification.
(5 mL) were added to the reaction mixture, which was
h, the reaction was worked-up with concentrated HCl
the reaction mixture was extracted into ethyl acetate (3
ere combined and the crude product was concentrated
rude product was used for the next stage without further
mL) was added to the crude product from the
he reaction mixture was heated at reflux. After 16 h, the
d with saturated NaHCO3 solution at 0 °C and acidified
n until pH 2. The reaction mixture was extracted into
The combined organic layers were concentrated under
tion over silica gel (hexane/ethyl acetate; 8:2) afforded
50%) as a colourless oil.
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δH (300 MHz, CDCl3) 7.65-7.41 (4H, m, Ar-H) 3.06 (2H, t, J = 7.7 Hz, CH2) and 2.76
(2H, t, J = 7.7 Hz, CH2); δc (300 MHz, CDCl3) 141.0 (Ar C), 131.8 (Ar CH), 129.0
(Ar CH), 125.0 (Ar CH), 123.3 (Ar CH), 35.5 (CH2) and 30.2 (CH2); δF (400MHz,
CDCl3): 62.4 (1F, d, J = 149.5 Hz, Feq) and 83.9 (4F, q, Faxial); IR (nujol mull)
υmax/cm-1 3353, 3006, 1484, 1313, 1272, 1109, 886, 827 and 764. m/z (ESI+) 299
[M+Na+] (50). HRMS (ESI+): Found 299.0141. Calcd. For [M+Na]+ C9H9SF5O2,
299.0136.
3-(3-(Pentafluorosulfur)phenyl)propan-1-ol 156.
Lithium aluminium hydride (206 m
3.6 mmol) in THF (30 mL). The r
reaction mixture was quenched
mixture was extracted into EtOAc
give the title compound 156 (848.
δH (400 MHz, CDCl3) 7.61-7.38 (
t, J = 7.8 Hz, CH2) and 1.93 (2H
128.6 (Ar CH), 125.7 (Ar CH),
(CH2); δF (400 MHz, CDCl3): 62
IR (nujol mull) υmax/cm-1 3351, 2
(CI+) 243 [M-F-] (100). HRMS (C
243.0467.168
g, 5.4 mmol) was added to a solution of 155 (1.0 g,
eaction mixture and heated under reflux for 1 h. The
with saturated NaHCO3 (15 mL). The reaction
 (3 х 50 mL). Concentration of the reaction crude to 
8 mg, 90%) as a colourless oil.
4H, m, Ar-H) 3.7 (2H, t, J = 6.3 Hz, CH2) 2.82 (2H,
, m, CH2); δc (400 MHz, CDCl3) 131.6 (Ar CH),
123.5 (Ar CH), 61.8 (COH), 33.9 (CH2) and 31.9
.4 (1F, d, J = 149.8 Hz, Feq) and 84.4 (4F, q, Faxial);
937, 1434, 1328, 1274, 1110, 918, 824 and 744. m/z
I+): Found 243.0464. Calcd. For [M-F]+ C9H11OF3S,
3-(3-(pentafluorosulfur)phenyl)propanal 157.
Dess-Martin Periodinane (1.9 g, 4
mmol) in dry DCM (20 mL) at 0
RT. After 1 h of stirring, the reac
(30 mL). The aqueous layer was 
organic layers were concentrated
(hexane: EtOAc; 9:1) gave the titl
δH (400 MHz, CDCl3) 9.76 (1H,
7.4 Hz, CH2) and 2.76 (2H, t, J =
141.6 (Ar C), 131.6 (Ar CH), 12
(CH2) and 27.8 (CH2); δF (400M
84.1 (4F, q, Faxial); IR (nujol mull
805 and 783. m/z (CI+) 241 [M-F
[M-F]+ C9H9OF3S, 243.0310.169
.58 mmol) was added to a solution of 156 (0.8 g, 3.0
°C and the reaction mixture was slowly warmed to
tion was quenched with saturated NaHCO3 solution
washed with EtOAc (3 х 50 mL) and the combined 
under reduced pressure. Purification over silica gel
e compound 157 (0.7 g, 90%) as a colourless oil.
s, CHO), 7.52-7.29 (4H, m, Ar-H) 2.95 (2H, t, J =
7.4 Hz, CH2); δc (400 MHz, CDCl3) 200.3 (C=O),
8.9 (Ar CH), 125.8 (Ar CH), 124.0 (Ar CH), 44.9
Hz, CDCl3): 62.4 (1F, d, J = 150.09 Hz, Feq) and
) υmax/cm-1 3006, 1710, 1484, 1435, 1275, 1100, 828,
-] (100). HRMS (CI+): Found 241.0310. Calcd. For
3’’-SF5- Cinacalcet HCl 137.
(R)-1-(1-Napthyl)ethylam
g, 0.7 mmol) in THF an
mg, 0.9 mmol) was then
h at RT. The reaction w
silica gel (hexane: EtOA
mL, 1M) to give to the ti
[]D +14.0 (c 0.4, CHC
(1H, brm, CH), 2.69 (2H
1.91 (3H, d, J = 6.0 Hz
132.0 (Ar C), 131.3 (Ar
CH), 127.4 (Ar CH), 12
123.8 (Ar CH), 121.2 (A
(CH2); δF (400 MHz, CD
IR (nujol mull) υmax/cm
[M+H+] (100). HRMS
416.1471.170
ine (0.15 mL, 0.9 mmol) was added to a solution of 157 (0.2
d stirred at RT for 5 h. Sodium triacetoxyborohydride (0.19
added into the reaction mixture and stirring continued for 16
as concentrated under reduced pressure. Purification over
c; 8:2) and followed by addition of HCl in diethyl ether (0.1
tle compound 137 (0.28 g, 90%) as a colourless oil.
l3); δH (400 MHz, CDCl3): 8.15-7.38 (11H, m, Ar-H), 5.11
, brm, CH2), 2.47 (2H, brm, CH2), 2.19 (2H, brm, CH2) and
, CH3); δc (400 MHz, CDCl3) 141.0 (Ar C), 133.8 (Ar C),
C), 130.6 (Ar CH), 129.6 (Ar CH), 129.5 (Ar CH), 128.7 (Ar
6.3 (Ar CH), 126.1 (Ar CH), 125.6 (Ar CH), 125.0 (Ar CH),
r CH), 53.5 (C), 45.4 (CH2), 32.6 (CH2), 27.3 (CH2) and 21.3
Cl3): 62.4 (1F, d, J = 150.09 Hz, Feq) and 84.0 (4F, q, Faxial);
-1 2925, 2848, 1275, 1261, 845, 805 and 750. m/z (ESI+) 416
(ES+): Found 416.1469. Calcd. For [M+H]+ C21H23NF5S,
Cinacalcet HCl 117.[6]
Cinacacet HCl was synth
This product was obtained
[]D +10.0 (c 1, CHCl3); δ
q, CH), 2.71-2.46 (4H, m,
MHz, CDCl3): -63.0 (3F,
accordance with the literat171
esized following a published method6, starting with 140.
as a pale yellow oil (2.4 g, 80%). []D +8.7 (c 1, CHCl3) lit.
H (400 MHz, CDCl3): 8.12-7.21 (11H, m, Ar-H), 4.57 (1H,
2×CH2) and 1.75 (3H, d, J = 6.44 Hz, CH3); δF {1H} (400
s, CF3). m/z (ESI+) 416 [M+H+] (100). These data were in
ure.6
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5.3 GC-MS analysis for determination of enantiopurity of product
(R)-147 and (S)-147.
Chiral phase GC-MS analysis was achieved using a BetadexTM 120 fused silica
capillary column (30 m × 0.25 mm i.d., 0.25 μM film thickness). The conditions used
for GC-MS analysis of (R)-147 were: oven held at 80 °C for 20 min, then a gradient at
20 °C/min to 150 °C, 250 °C injector temperature; 100:1 split ratio, 1.0 mL/min flow.
The GC-MS chromatogram presented in Figure 5.1 shows a major peak at the
retention time of 36.24 min, which corresponds to (R)-147 ([M]+., m/z = 220, while
the minor peak shown at the retention time of 33.16 min was assigned to be the
difluorinated compound ([M]+., m/z = 238). The enantiomeric ratio of (R)-147
determined from the chiral phase GC-MS was found to be 99%ee. The MS (EI)
spectra of the peak at 33.16 (Figure 5.2) and 36.24 min (Figure 5.3) showed an
identical fragment pattern of m/z = 159, which corresponds to [M-CHFCHO]+ of the
(R)-147 and 151.
Figure 5.1. The chiral phase GC chromatogram of th
start at 80 °C held for 20 min, the gradient at 20 °C
temperature, 100:1 split ratio, 1.0
36.24 1370606 20Retention
time
( min)
Area
(units)
Ratio
33.16 68530.3 1e crude (R)-147. (99 % ee): oven
/min to 150 °C), 250 °C injector
mL/min flow.
Figure 5.2. Mass spectrum of the GC peak at 36.2 min showing the presence of
(R)-147.
[M]+.Figure 5.3. M173
ass spectrum of the GC peak at 33.1 min showing the presence of
151.
[M]+.
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A similar procedure was applied to the other enantiomer (S)-147. The GC-MS
chromatogram presented in Figure 5.4 showed a major peak at retention time 36.26
min, which corresponded to (S)-147 ([M]+., m/z = 220), while the minor peak at
retention time 33.17 min was assigned to the difluorinated compound 151 ([M]+., m/z
= 238). The enantiomeric ratio of (S)-147 determined from the chiral phase GC-MS
was found to be 99%. The MS (EI) spectra of the peak at 36.26 min (Figure 5.5) was
found to have identical fragment pattern with the Figure 5.3, with (m/z = 159
[M-CHFCHO]+., m/z = 200 [M-F-], m/z = 220 [M]+.), confirms that (S)-147 are
enantiomer of each other.
Figure 5.4. The chiral phase GC chromatogram of the crude (S)-147. (99 % ee): oven
start at 80 °C held for 20 min, the gradient at 20 °C/min to 150 °C), 250 °C injector
temperature, 100:1 split ratio, 1.0 mL/min flow.
Retention
time
( min)
Area
(units)
Ratio
33.17 71268.4 1
36.26 1187808 16.7
Figure 5.5. Mass spectrum of the GC peak at 36.2 min showing the presence of
(S)-147.
Figure 5.6. Mas
[M]+.s175
spectrum of the GC peak at 33.1 min showing the presence of 151.
[M]+.
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Appendix 1
Table 1. Crystal da
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficie
F(000)
Crystal size
Theta range for data177
ta and structure refinement for 93
pcdh16
C22 H29 N O9
451.46
93(2) K
0.71073 Å
Triclinic
P-1
a = 9.595(9) Å = 94.97(2)°.
b = 9.918(10) Å = 92.058(12)°.
c = 13.558(11) Å  = 112.66(2)°.
1182.9(19) Å3
2
1.268 Mg/m3
nt 0.099 mm-1
480
0.30 x 0.10 x 0.10 mm3
collection 2.56 to 25.39°.
178
Index ranges -10<=h<=11, -11<=k<=11, -13<=l<=16
Reflections collected 7410
Independent reflections 4168 [R(int) = 0.1465]
Completeness to theta = 25.30° 96.6 %
Absorption correction Multiscan
Max. and min. transmission 1.000 and 0.740
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 4168 / 2 / 298
Goodness-of-fit on F2 1.299
Final R indices [I>2sigma(I)] R1 = 0.1447, wR2 = 0.3596
R indices (all data) R1 = 0.1635, wR2 = 0.3995
Extinction coefficient 0.11(3)
Largest diff. peak and hole 0.632 and -0.447 e.Å-3
Appendix 2
Crystal data and str
Empirical Formula
Formula Weight
Crystal Color, Hab
Crystal Dimension
Crystal System
Lattice Type
Lattice Parameters179
ucture refinement for (-)-73
C5H9ClFNO4
201.58
it colorless, needle
s 0.100 X 0.030 X 0.010 mm
triclinic
Primitive
a = 5.064(2) Å
b = 5.638(2) Å
c = 6.877(3) Å
 = 110.97(2) o
 = 98.24(2) o
 = 105.14(2) o
V = 170.75(11) Å3
180
Space Group P1 (#1)
Z value 1
Dcalc 1.960 g/cm3
F000 104.00
(CuK) 50.302 cm-1
Appendix 3
Table 1. Crystal data an
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Theta range for data colle
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 6
Absorption correction
Max. and min. transmissi
Refinement method
Data / restraints / parame
Goodness-of-fit on F2181
d structure refinement for (R,R)-139.
pcdh27
C22 H22 Cl F4 N
411.86
173(2) K
1.54178 Å
Orthorhombic
P2(1)2(1)2(1)
a = 7.2710(4) Å = 90°.
b = 13.0197(6) Å = 90°.
c = 22.3322(11) Å  = 90°.
2114.11(18) Å3
4
1.294 Mg/m3
1.967 mm-1
856
0.12 x 0.05 x 0.05 mm3
ction 3.93 to 68.06°.
-8<=h<=8, -15<=k<=15, -26<=l<=26
26693
3740 [R(int) = 0.0433]
7.00° 98.3 %
Multiscan
on 1.000 and 0.723
Full-matrix least-squares on F2
ters 3740 / 2 / 250
1.039
182
Final R indices [I>2sigma(I)] R1 = 0.0704, wR2 = 0.1892
R indices (all data) R1 = 0.0726, wR2 = 0.1918
Absolute structure parameter 0.05(3)
Largest diff. peak and hole 0.972 and -0.609 e.Å-3
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